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ABSTRACT 
With the growing worldwide prevalence of antibiotic-resistant strains of tuberculosis (TB), new 
targets are urgently required for the development of treatments with novel modes of action. 
Fumarate hydratase (fumarase), a vulnerable component of the citric acid cycle in Mycobacterium 
tuberculosis (Mtb), is a metabolic target that could satisfy this unmet demand. A key challenge in 
the targeting of Mtb fumarase is its similarity to the human homolog, which shares an identical 
active site. A potential solution to this selectivity problem was previously found in a high-
throughput screening hit that binds in a non-conserved allosteric site. Optimization of this inhibitor 
is complicated by its unique dimeric-binding mode, with the two molecules in the allosteric site 
interacting with each other in addition to holding together two of the protein subunits in an inactive 
conformation. In this work, a structure-activity relationship study was carried out with the 
determination of further structural biology on the lead series, affording derivatives with sub-
micromolar inhibition. Further, the screening of this series against Mtb in vitro identified 
compounds with potent MICs. Together, these results encourage further work on Mtb fumarase as 





Mycobacterium tuberculosis (Mtb), the causative agent of the disease tuberculosis (TB), infects 
10 million people per year and is responsible for the deaths of 1.6 million annually, of which 
300,000 are HIV-positive.1 Further, a quarter of the global population, 1.7 billion individuals, are 
infected with asymptomatic latent TB and hence at risk of active infection.2 Despite the scope of 
the disease, treatment remains intensive and long-term with multi- and extensively-drug resistant 
TB strains a growing problem, hence there is a continuing urgent need for novel improved anti-
TB therapeutics.3 
Mtb fumarate hydratase (fumarase) is a component of the citric acid cycle in Mtb,4 where it 
catalyzes the reversible interconversion of fumarate and L-malate. When normoxic cells are 
rapidly dividing fumarase operates in the forward direction (fumarate to L-malate) and is involved 
in energy generation and the synthesis of precursors for biosynthetic pathways. Under conditions 
of lowered oxygen availability fumarase operates in the reverse direction allowing fermentative 
production and secretion of succinate.5,6 During pathogenesis of tuberculosis anoxia develops in 
the center of caseous lesions prior to the development of cavitary lesions, where sudden reaeration 
allows rapid bacterial growth to promote bacterial transmission from host-to-host.7 Mtb fumarase 
is a non-redundant and therefore vulnerable component of the citric acid cycle,8 a situation that is 
not guaranteed in bacteria.9 The regulation of fumarase is therefore central to the realignment of 
bacterial metabolism that occurs during normal disease progression in Mtb, which makes it a very 
high value target for drugs that might allow faster bacterial clearance. Mtb fumarase has been 
shown to be essential for Mtb survival with depletion linked to impaired growth due to 
accumulation of fumarate, which can react with cysteine thiols.10 This modification adversely 
impacts the antioxidants catalase and mycothiol, inducing hypersensitivity to oxidative stress and 
ultimately Mtb death both in vitro and in vivo. 
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Mtb fumarase is a 210 kDa class II fumarase,11 characterized by thermostability, iron-
independence and a homotetrameric structure.9,12 Each subunit is defined by an N-terminal domain 
(residues 1-137), a central domain (residues 138-393) whose α-helices pack with those from other 
subunits to form a central 20-helix bundle that holds together the quaternary structure, and a 
conformationally flexible C-terminal domain (residues 394-474). The protein possesses four 
symmetry-related active sites, each located in clefts formed by three subunits and covered by an 
‘SS’ loop (residues 316-325) that can switch between ‘open’ and ‘closed’ states.11 The selective 
targeting of Mtb fumarase is challenging due to its 53% overall sequence identity with the human 
homolog, which was recently the focus of a study on cancer cell lines.13 In our previous work, the 
conservation of active site residues between Mtb and human fumarase was circumvented through 
the discovery by high-throughput screening (HTS) of an allosteric inhibitor 1 of Mtb fumarase 
(IC50 2.5 ± 1.1 µM) (Figure 1a).
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Figure 1. a) Allosteric inhibitor 1 of Mtb fumarase;14 X-ray crystal structure of Mtb fumarase in 
complex with 1 (PDB code 5F91, subunit A = white, subunit B = green, subunit C = cyan, subunit 
D = yellow),14 illustrating b) relative locations of the allosteric and active sites in the 













X-ray crystallography showed that inhibitor 1 binds dimerically to Mtb fumarase at the interface 
between two adjacent C-terminal domains in an induced pocket (Figure 1b), locking the nearest 
active site in an ‘open’ conformation, with the bound molecules interacting with each other through 
π-stacking of their central phenyl rings (Figure 1c).14 A second symmetry-related allosteric site 
exists in the homotetramer however this is unoccupied in the X-ray crystal structure (Figure 1b), 
likely due to its participation in a crystal contact. Whilst 1 did not exhibit bactericidal properties it 
was able to exert moderate inhibition of Mtb growth in vitro (65% inhibition at 250 µM) that, in 
combination with the demonstrated essentiality of Mtb fumarase,8,10 warranted additional 
investigation into inhibitor 1. Due to the dimeric-binding mode of 1, a possible strategy would be 
to link the molecules together into one inhibitor, however the geometry of the π-stacking 
interaction makes this route challenging. One way of circumventing this problem could be the use 
of a deconstruction-reconstruction approach,15 where the HTS hit is defragmented into fragment-
like molecules allowing the identification of key binding motifs. This would allow the use of 
fragment-based methods to more effectively sample the ligand-binding site and develop a sub-
micromolar inhibitor with activity against Mtb in vitro.16 
 
RESULTS AND DISCUSSION 
Defragmentation of HTS hit 1. The defragmentation of HTS hit 1 into ‘fragment-like’ 
molecules resulted in the assembly of a focused library (Table 1), with members spanning a range 
of molecular weights (204 to 326 Da) and incorporating various binding motifs of 1. The screening 
of the library with a biochemical assay afforded no measurable inhibition at concentrations of 100 
µM or 1 mM (data not shown). Similarly, the use of differential scanning fluorimetry (DSF) 
showed either negligible change in the melting temperature (ΔTm +0.1 °C for 10) or negative 
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thermal shifts (ΔTm -1.6 °C for 7) at a ligand concentration of 5 mM (Table 1), in contrast to the 
thermal shift of +3.9 °C afforded by 1 at 0.625 mM. This includes the higher molecular weight 
compounds in the library 4 (ΔTm -0.4 °C) and 6 (ΔTm -0.6 °C), which retain the substituted phenyl 
ring of 1 in addition to either of the sulfonamide or phthalazinone motifs. These results suggest 
that the inhibitory capability of 1 for Mtb fumarase is dependent upon all its binding motifs, with 
high sensitivity to truncation. The negative impact of defragmentation is not surprising due to the 
large number of interactions that doubly-binding 1 makes in the allosteric site with the two C-
terminal domains of Mtb fumarase (in addition to itself through the π-stacking interaction of its 
phenyl ring), as well as the induced nature of the site with cryptic pockets not easily targeted by 
weak fragments.  
  
Table 1. The change in the melting temperatures (Tm) of compounds 2-11. 
Compound ΔTm

























-0.6  11 
 
-0.4 
a 5 mM ligand and 2.5 μM Mtb fumarase.  
 
Structure-activity Relationship Study of HTS hit 1. Due to lack of success in defragmentation 
of the HTS hit 1, attention was shifted to a structure-activity relationship study. Initial modification 
of the central phenyl ring of 1 through the removal of its methoxy group, which indirectly engages 
Leu303, Gly305, Leu306 and His397 through hydrogen bonds with two ordered water molecules 
(Figure 2), was not tolerated in 12 (16% inhibition at 50 µM) (Table 2). A similar result was seen 
upon replacement of the methoxy group with a methyl group in 13 (<10% inhibition at 50 µM), 
illustrating the sensitivity of the central phenyl ring of 1 to alteration. The replacement of the 
sulfonamide group with an amide, and the resultant rigidification and rotation of the azepanyl ring 
was also not tolerated in 14 (14% inhibition at 50 µM). 
 
Figure 2. X-ray crystal structure of Mtb fumarase in complex with 1 (PDB code 5F91, subunit A 
= white, subunit B = green, subunit C = cyan, subunit D = yellow),14 illustrating the interactions 




Table 2. The inhibition at 50 µM ligand concentration afforded by compounds 1 and 12-14. 
Compound Structure 
Inhibition (%) 












14 ± 1 
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The replacement of the phthalazinone ring of HTS hit 1 with an indole in 15a (27% inhibition 
at 50 µM) resulted in a significant drop in inhibition (Table 3), despite X-ray crystallography 
showing the maintenance of the cation-π interaction with Arg432 and a hydrogen-bond with the 
backbone carbonyl of Leu429 (Figure 3a). The substitution of the ring in 15b (38% inhibition at 
50 µM) or extension of the linker in 15c (12% inhibition at 50 µM) did not result in a significant 
improvement on 15a. The use of alternative 5-6 fused rings including benzofuran (15d), 
benzisoxazole (15e) and benzimidazole (15f) derivatives failed to provide inhibition in the 
biochemical assay at 50 µM. In contrast, the screening of quinoline derivative 15g (IC50 4.1 µM) 
resulted in a comparable IC50 value to 1 (IC50 2.0 µM), with the X-ray crystal structure of the Mtb 
fumarase-15g complex showing the quinoline ring hydrogen-bonding to a water molecule as 
opposed to the protein backbone (Figure 3b). Truncation of the quinoline ring of 15g to a pyridine 
in 15i eliminated inhibitory activity at 50 µM, in a similar manner to the defragmentation of 1.  
 
Figure 3. X-ray crystal structures of Mtb fumarase (subunit A = white, subunit B = green, subunit 
C = cyan, subunit D = yellow) in complex with a) 15a (PDB code 6S7U) and b) 15g (PDB code 





Table 3. The inhibition at 50 µM ligand concentration or half-maximal inhibitory concentrations 







at 50 µM 
 Compound R 
Inhibition (%) 
at 50 µM 
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38 ± 5  15g 
 
86 ± 2b 
15c 
 
12 ± 9  15h 
 
21 ± 17 
15d 
 
< 10  15i 
 
< 10 
a IC50 2.0 ± 0.1 µM, consistent with previously reported value.
14 
b IC50 4.1 ± 0.3 µM. 
 
The truncation of HTS hit 1 to the N-methyl sulfonamide 16a (IC50 57 µM) afforded the lowest 
molecular weight derivative (402 Da) to give a measurable IC50 value (Table 4). An X-ray crystal 
structure was obtained of the complex of 16a with Mtb fumarase, illustrating a 5 Å movement in 
the Arg400 side chain (at Cε) relative to the complex with 1 to form a salt-bridge with Glu396, 
significantly reducing the apparent volume for growth around the sulfonamide (Figure 4a). 
Heterocyclic derivatives of 1 were also produced to explore the volume defined by His397, Arg400 
and Arg432, beginning with the azocanyl and piperidinyl analogues 16b (IC50 4.0 µM) and 16c 
 13 
(IC50 4.4 µM). These 8- and 6-membered derivatives possessed slightly attenuated inhibition in 
comparison to 1 (IC50 2.0 µM), however were not sufficiently different to preclude testing of 
alternative heterocycles of similar size. X-ray crystallography showed no significant difference in 
the binding mode of 16b in Mtb fumarase in comparison to 1 except for Arg400 located above the 
larger 8-membered ring, which showed evidence of a second alternative conformation (Figure 4b). 
The N-methyl piperazinyl derivative 16d (IC50 38 µM), along with morpholino and thiomorpholine 
dioxide analogues 16e (IC50 12 µM) and 16g (IC50 13 µM) afforded IC50 values weaker than 1 or 
the thiomorpholino derivative 16f (IC50 4.7 µM). 
 
Figure 4. X-ray crystal structure of Mtb fumarase (subunit A = white, subunit B = green, subunit 
C = cyan, subunit D = yellow) in complex with a) 16a (PDB code 6S7K) and b) 16b (PDB code 






Table 4. The inhibition at 50 µM ligand concentration or half-maximal inhibitory concentrations 
(IC50) afforded by compounds 16a-n. 
 
Compound R IC50 (µM)  Compound R IC50 (µM) 
16a  57 ± 3  16h 
 
17 ± 3 
16b 
 





4.4 ± 0.1  16j 
 
2.2 ± 0.2 
16d 
 
38 ± 2  16k 
 





12 ± 1  16l 
 
0.67 ± 0.03 
16f 
 
4.7 ± 0.2  16m 
 
0.67 ± 0.01 
16g 
 
13 ± 1  16n 
 
NDb 
a 53 ± 3% inhibition at 50 µM concentration. 
b 44 ± 5% inhibition at 50 µM concentration. 
 
The replacement of the methyl group of 16a with a phenyl ring in 16h (IC50 17 µM) (Table 4) 
partially restored the conformation of the Arg400 side chain, with observation of a cation-π 
interaction by X-ray crystallography (Figure S8). The addition of more flexibility to 16h in 16i 
through insertion of a methylene linker had a detrimental impact on inhibition (53% inhibition at 
50 µM). The rigidification of 16i through incorporation of its benzyl group into a 
tetrahydroisoquinolyl ring system in 16j (IC50 2.2 µM) was more successful, with comparable 
inhibition to 1 (IC50 2.0 µM). X-ray crystallography showed the tetrahydroisoquinolyl ring of 16j 
lying between Arg400 and Arg432, with the side chain of Arg400 maintaining the conformation 
exhibited in the Mtb fumarase-16h structure through a cation-π interaction with the phenyl portion 
of the ring (Figure 5a). Ring expansion of 16j to improve the interaction with Arg432 in 16l (IC50 
0.67 µM) resulted in a sub-micromolar IC50 value, 3-fold lower than that of 1 (IC50 2.0 µM) (Figure 
5b). Addition of a methoxy group in 16m (IC50 0.67 µM) maintained the sub-micromolar 
inhibitory profile, however further modification of 16l through addition of a methylene bridge to 
the tetrahydrobenzoazepanyl ring in 16n was not tolerated (44% inhibition at 50 µM), revealing 
the limits of occupancy of this pocket in the allosteric site. 
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Figure 5. X-ray crystal structure of Mtb fumarase (subunit A = white, subunit B = green, subunit 
C = cyan, subunit D = yellow) in complex with a) 16j (PDB code 6S7Z) and b) 16l (PDB code 







Screening against H37Rv Mycobacterium tuberculosis. As previously reported,14 no 
bactericidal activity was observed for HTS hit 1 (Table 5). This was also found with derivatives 
15g-i, 16c-h and 16j-m (data not shown). However, activity was observed with 15a-d and 16b 
(Table 5). The balance of metabolic intermediates in Mtb can be programmed by feeding the 
bacterium various carbon sources. As such, Mtb growing under glucose as the sole carbon source 
relies on glycolysis while bacteria that grow on dipalmitoyl phosphatidylcholine (DPPC) will rely 
heavily on β-oxidation to supply intermediates for the central carbon metabolism. Because 
pyruvate from glycolysis will go on to feed several other anabolic pathways, on balance bacteria 
get more acetyl-CoA equivalence under growth in DPPC. These acetyl-CoA feed directly into the 
citric acid cycle (among other pathways) in which fumarase lies. Therefore, the flux of 
intermediates in the citric acid cycle is greater under growth in DPPC and Mtb are more reliant on 
the activity of enzymes in this pathway for growth. Hence, it is reassuring that compounds 15a-d 
and 16b were highly active in DPPC-containing medium. In particular, the benzofuran analogue 
15d gave the lowest MIC value against Mtb at 6.3 µM in DPPC-containing medium. Of these 
active compounds 16b (IC50 4.0 µM, MIC 19 µM in 7H9/DPPC) was the most potent against 
purified Mtb fumarase, and all were more lipophilic than 1 (cLogP 1.6) with the majority 
possessing a cLogP between 3.6 and 4.1. The poor activity in 7H9 medium supplemented with 
ADC was likely due to high protein binding since this medium contains 0.4% bovine serum 
albumin. This suggests overcoming protein binding will be an important component of future 
optimization. 
 
Table 5. The minimum inhibitory concentrations (MIC) against H37Rv Mycobacterium 
tuberculosis (Mtb) afforded by compounds 1, 15a-d and 16b. 
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Compound R1 R2 cLogPa H37Rv Mtb MIC (µM) 












1.6 > 100 > 100 > 100 > 100 
15a 
  




3.6 > 100 > 100 > 100 12.5 
15c 
  
4.1 > 100 > 100 25 9.4 
15d 
  




2.1 > 100 > 100 25 19 
a Calculated using ChemDraw (PerkinElmer, Waltham MA). 
 
Synthetic Chemistry. The synthesis of 1 was achieved in a convergent manner with the T3P®-
mediated amide coupling of carboxylic acid 3 and aniline 5 (60% yield) (Scheme 1), each produced 
as previously reported.14 Synthesis of aniline 5 involved the trifluoroacetyl-protection of the amino 
group of o-anisidine 19 as 20 (99% yield), followed by SEAr of a sulfonyl chloride group by 
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treatment with chlorosulfonic acid (77% yield). Reaction of 21 with hexamethyleneimine and 
sodium hydride converted the sulfonyl chloride to a sulfonamide, with the resultant intermediate 
heated under reflux in an aqueous mixture of ethanol and HCl to remove the trifluoroacetyl 
protecting group, affording 5 (83% yield). Carboxylic acid 3 was obtained by a route beginning 
with the Horner-Wadsworth-Emmons reaction of phthalic anhydride 17 and 
(carbethoxymethylene)triphenylphosphorane to give 18 (67% yield), followed by heating under 
reflux with hydrazine in ethanol to afford the phthalazinone ester 2 (99% yield). Hydrolysis of 2 
produced acid 3 (44% yield), which was also used in the synthesis of 4 through T3P®-mediated 
amide coupling with o-anisidine 19 (82% yield) (Scheme 1). The application of acetic anhydride 
and pyridine to aniline 5 also allowed the production of 6 (79% yield). 
 




Reagents and Conditions: (a) (carbethoxymethylene)triphenylphosphorane, CHCl3, reflux, 3 h; 
(b) N2H4·H2O, EtOH, 50 
°C, 2 h; (c) NaOH (10% w/v), THF, reflux, 1 h; (d) TFAA, pyridine, 
DCM, 0 °C to rt, 3 d; (e) HSO3Cl, DCM, 0 
°C to rt, 16 h; (f) (i) hexamethyleneimine, NaH, DMF, 
0 °C to rt, 3 h (ii) EtOH, HCl (37.5% w/v), H2O, reflux, 20 h; (g) T3P
® (50 wt. % in DMF), DIPEA, 
DMF, 70 °C, 1 h; (h) 19, T3P® (50 wt. % in DMF), DIPEA, DMF, 40 °C, 2 h; (i) Ac2O, pyridine, 
DCM, 90 min. 
 
Fragment 7 was synthesized in three steps, beginning with the treatment of phenol 22 with 
chlorosulfonic acid in a similar manner to 20 (78% yield) (Scheme 2). The resultant sulfonyl 
chloride 23 was reacted with hexamethyleneimine in the presence of DIPEA to afford sulfonamide 
24 (64% yield), whose nitro group was reduced by a mixture of sodium borohydride and nickel(II) 
chloride (62% yield). The production of fragment 8 and the corresponding methyl analogue 29 
involved the functionalization of commercial sulfonyl chlorides 25 and 26 with 
hexamethyleneimine and sodium hydride, affording sulfonamides 27 and 28 (42-72% yield) 
(Scheme 2). The nitro groups of 27 and 28 were reduced in the same manner as 24 to the 
corresponding anilines 8 and 29 (82-88% yield). Aniline 8 was also acetylated to fragment 9 in the 
same manner as 5 (86% yield). Anisole 30 was used to make fragment 10 through stirring with 
chlorosulfonic acid, with the resultant sulfonyl chloride taken forwards crude for reaction with 
hexamethyleneimine and sodium hydride (49% yield overall) (Scheme 2). The sulfonyl chloride 
21 was converted to N-methyl sulfonamide 31a by heating under reflux with methylamine in THF 
(82% yield), with 31a also acetylated in the same manner as 5 to afford fragment 11 (56% yield). 
 







Reagents and Conditions: (a) HSO3Cl, CHCl3, 0 °C to reflux, 90 min; (b) hexamethyleneimine, 
DIPEA, DCM, 15 h; (c) NaBH4, NiCl2·6H2O, MeOH, 0 °C to rt, 2 h; (d) hexamethyleneimine, 
NaH, DMF, 0 °C to rt, 1 h to 90 min; (e) NaBH4, NiCl2, MeOH, 0 
°C to rt, 45 min; (f) Ac2O, 
pyridine, DCM, 5 h; (g) (i) HSO3Cl, CHCl3, 0 °C to rt, 30 min (ii) hexamethyleneimine, NaH, 
DMF, 0 °C to rt, 1 h; (h) (i) methylamine (2 M in THF), THF, reflux, 90 min (ii) EtOH, HCl 
(37.5% w/v), H2O, reflux, 3 h 30 min; (i) Ac2O, pyridine, DCM, 2 d. 
 
Compounds 12 and 13 were synthesized using anilines 8 and 29 (Scheme 2), which were coupled 
with carboxylic acid 3 using T3P® as with the synthesis of 1 (45-50% yield) (Scheme 3). In 
contrast, the route for 14 required the initial T3P®-mediated amide coupling of carboxylic acid 32 
with hexamethyleneimine, affording phenol 33 (24% yield) that was methylated with methyl 
iodide (77% yield) (Scheme 3). The nitro group of 34 was reduced in the same manner as 27 and 
28 (64% yield), with the resultant aniline 35 coupled with acid 3 to afford 14 (45% yield). 
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Reagents and Conditions: (a) T3P® (50 wt. % in EtOAc), DIPEA, DMF, 70 °C, 2 h; (b) 
hexamethyleneimine, T3P® (50% in DMF), DIPEA, DMF, 1 d; (c) Me2SO4, K2CO3, acetone, 
reflux, 2 h; (d) NaBH4, NiCl2·6H2O, MeOH, 0 
°C to rt, 90 min; (e) 3, T3P® (50 wt. % in EtOAc), 
DIPEA, DMF, 70 °C, 2 h. 
 
Compounds 15a-f and 15h were synthesized in one step from aniline 5 via T3P®-mediated amide 
coupling with commercially available carboxylic acids (21-67% yield), whilst 15i required 
alternative amide-coupling conditions with the use of EDC (64% yield) (Scheme 4). In the 
production of 15g, 4-methylquinoline 36 was converted using LDA and carbon dioxide to 4-
quinolylacetic acid, which was taken forwards crude for reaction with aniline 5 (5% yield overall). 
The synthesis of compounds 16a-n involved the T3P®-mediated amide coupling of anilines 31a-
n with carboxylic acid 3 as with the synthesis of 1 (10-43% yield) (Scheme 4). Anilines 31b-f and 
31h-l were produced by the reaction of sulfonyl chloride 21 with commercially available amines 
in the presence of sodium hydride, followed by trifluoroacetyl deprotection via heating under 
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reflux with ethanol and HCl as in 5 (37-81% yield). In comparison, whilst the trifluoroacetyl 
deprotection step in the synthesis of anilines 31g and 31m-n was the same as 31b-f and 31h-l, the 
prior reaction of sulfonyl chloride 21 with an amine was carried out with triethylamine and DMAP 
(65-80% yield overall). 
 
Scheme 4. Synthesis of Compounds 15-16. 
……………………………………………………………………………………………………… 
 
Reagents and Conditions: (a) RCH2CO2H, T3P
® (50 wt. % in EtOAc), DIPEA, DMF, 70 °C, 1 
to 4 h; (b) 4-pyridylacetic acid HCl, EDC.HCl, DIPEA, DMAP, DCM, 90 min; (c) (i) CO2 (s), 
LDA (2 M in THF/heptane/ethylbenzene), THF, -78 °C to rt, 1 h (ii) 5, T3P® (50 wt. % in EtOAc), 
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DIPEA, DMF, 70 °C, 40 min; (d) (i) RH, NaH, DMF, 0 °C to rt, 30 min to 20 h (ii) EtOH, HCl 
(37.5% w/v), H2O, reflux, 9 h to 2 d; (e) (i) RH, NEt3, DMAP, DCM, 30 min to 1 h (ii) EtOH, HCl 
(37.5% w/v), H2O, reflux, 3 to 16 h; (f) T3P
® (50 wt. % in EtOAc), DIPEA, DMF, 70 °C, 45 min 
to 5 h. 
 
CONCLUSIONS 
The application of a deconstruction-reconstruction approach with the previously identified HTS 
hit 1 did not lead to the development of improved inhibitors, with defragmentation failing to afford 
fragments with either measurable inhibition in the biochemical assay or a positive result by DSF. 
This points to the essentiality of all components of 1 for its unique dimeric, induced-fit binding 
mode in the allosteric site of Mtb fumarase. A subsequent SAR study of 1 showed that 
modifications including replacement of both the phthalazinone and azepanyl ring systems were 
possible, with benzoazepanyl derivatives 16l-m affording sub-micromolar IC50 values (0.67 µM) 
three-fold stronger than that of 1. Derivatives of 1 maintained the dimeric-binding mode in the 
allosteric site of Mtb fumarase under X-ray crystallography soaking conditions, including in the 
case of attenuated inhibition as in 16a (IC50 57 µM). In contrast to 1, a subset of the derivatives 
afforded measurable MIC values against Mtb in vitro. These derivatives ranged from conservative 
expansion of the azepanyl ring of 1 with a subsequent rise in lipophilicity in 16b (MIC 19 µM in 
7H9/DPPC) to complete replacement of the phthalazinone ring with alternative heterocyclic 
systems in 15a-d (MIC 6.3-12.5 µM in 7H9/DPPC). These results represent a significant 
improvement on the original HTS hit 1 and encourage further work on Mtb fumarase as a target 




General Chemistry. All reactions were carried out in oven-dried glassware under a positive 
pressure of dry nitrogen atmosphere. Temperatures of 0 and -78 °C were obtained by submerging 
the reaction vessel in a bath containing either ice or a mixture of solid CO2 pellets and acetone 
respectively. The solvents DCM, ethyl acetate, acetonitrile, methanol, petroleum ether and toluene 
were distilled over calcium hydride under a dry nitrogen atmosphere prior to use, with THF 
distilled over a mixture of lithium aluminium hydride, calcium hydride and triphenylphosphine. 
DMF was purchased as anhydrous from commercial suppliers, with ethanol obtained in the 
absolute form. All purchased chemicals were used as received. Solutions of Na2CO3 and NaCl 
(brine) were aqueous and saturated. 
Flash column chromatography was performed using automated Biotage® Isolera™ Spektra 
purification systems with appropriately sized Biotage® SNAP cartridges, containing either KP 50 
µm silica in ‘normal phase’ purification or HP-sphere 25 µm C18 silica in ‘reverse phase’ 
purification. Analytical thin layer chromatography (TLC) was performed using Merck glass-
backed silica plates, with visualization by 254 or 365 nm ultraviolet light. 
Liquid chromatography mass spectrometry (LCMS) was carried out using a Waters® Acquity 
UPLC® H-Class system, with samples run on a solvent gradient from 0 to 95% acetonitrile in water 
(+ 0.1% formic acid) over 4 minutes. Peaks corresponding to desired product are described, 
including the retention time (rt) and % purity by integration. High resolution mass spectrometry 
(HRMS) was mainly performed using ThermoFinnigan Orbitrap Classic, Waters® LCT PremierTM 
or Waters® VionTM IMS QTof systems. A Perkin-Elmer® Spectrum One FT-IR spectrometer fitted 
with a universal attenuated total reflectance accessory was used to record infrared spectra, with 
wavelengths of maximum absorbance (νmax) quoted in wavenumbers (cm
-1) for signals outside of 
the fingerprint region (br = broad). Only peaks corresponding to key functional groups were 
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characterized. Nuclear magnetic resonance (NMR) spectra were recorded in the indicated 
deuterated solvents with AvanceTM III HD (400 MHz), QNP Cryoprobe (400 MHz) or DCH 
Cryoprobe (500 MHz) Bruker spectrometers. 1H NMR data are presented in the following order: 
chemical shift (in ppm on a δ scale relative to the residual solvent resonance peak), integration, 
multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, quin = quintet, sep = septet, m = 
multiplet) and coupling constant (J, in Hz). 13C NMR spectra were proton-decoupled, with 
chemical shifts presented. 
A combination of TLC and LCMS analysis was used to monitor reactions. All tested compounds 
possessed a purity of at least 95% as determined by LCMS analysis. 
N-(5-(Azepan-1-ylsulfonyl)-2-methoxyphenyl)-2-(4-oxo-3,4-dihydrophthalazin-1-
yl)acetamide (1). T3P® (50 wt. % in DMF, 1.3 mL, 2.2 mmol) and N,N-diisopropylethylamine 
(0.64 mL, 3.7 mmol) were added to a solution of 2-(4-oxo-3,4-dihydrophthalazin-1-yl)acetic acid 
3 (0.150 g, 0.735 mmol) and 5-(azepan-1-ylsulfonyl)-2-methoxyaniline 5 (0.209 g, 0.735 mmol) 
in DMF (2 mL). The reaction mixture was heated to 70 °C over 1 hour. The reaction mixture was 
diluted with water (15 mL), adjusted to pH 1 and extracted into ethyl acetate (3 x 20 mL). The 
combined organic extracts were dried (MgSO4) and concentrated in vacuo. Purification by flash 
column chromatography (0 – 20% methanol in DCM) afforded 1 (0.206 g, 60% yield). LCMS 
(ESI+): m/z 471.3 [M + H]+, (ESI-): m/z 469.1 [M - H]-, rt 1.92 minutes, >99%; 1H NMR (400 
MHz, (CD3)2SO) 12.62 (1H, s), 9.86 (1H, s), 8.45 (1H, d, J = 2.1 Hz), 8.27 (1H, d, J = 7.9 Hz), 
7.99-7.91 (2H, m), 7.90-7.82 (1H, m), 7.49 (1H, dd, J = 8.5, 2.2 Hz), 7.24 (1H, d, J = 8.8 Hz), 4.21 
(2H, s), 3.96 (3H, s), 3.12 (4H, t, J = 5.9 Hz), 1.64-1.51 (4H, m), 1.50-1.39 (4H, m); 13C NMR 
(125 MHz, (CD3)2SO) 168.4, 159.5, 152.0, 142.1, 133.5, 131.6, 130.4, 129.8, 127.7, 127.6, 125.9, 
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125.5, 123.4, 119.1, 111.2, 56.3, 47.6, 28.5, 26.3 (1 peak missing); spectroscopic data consistent 
with literature.14 
Ethyl 2-(4-oxo-3,4-dihydrophthalazin-1-yl)acetate (2).14,17 Hydrazine monohydrate (0.47 
mL, 9.0 mmol) was added dropwise to a solution of ethyl (E)-2-(3-oxoisobenzofuran-1(3H)-
ylidene)acetate 18 (1.97 g, 9.03 mmol) in ethanol (10 mL). The reaction mixture was stirred at 50 
°C over 2 hours. The reaction mixture was cooled to room temperature and left to stand for 12 
hours. The resulting precipitate was obtained by vacuum filtration and washed with ethanol (10 
mL) to afford 2 (2.21 g, 99% yield). LCMS (ESI+): m/z 233.2 [M + H]+, rt 1.53 minutes, >99%; 
1H NMR (400 MHz, (CD3)2SO) 12.63 (1H, s), 8.30-8.24 (1H, m), 7.98-7.91 (1H, m), 7.90-7.83 
(2H, m), 4.11 (2H, q, J = 7.1 Hz), 4.05 (2H, s), 1.17 (3H, t, J = 7.1 Hz); 13C NMR (100 MHz, 
(CD3)2SO) 169.8, 159.4, 140.9, 133.6, 131.7, 129.4, 127.5, 125.9, 125.5, 60.7, 37.9, 14.0; 
1H NMR 
spectroscopic data consistent with literature.17 
2-(4-Oxo-3,4-dihydrophthalazin-1-yl)acetic acid (3).14 Ethyl 2-(4-oxo-3,4-
dihydrophthalazin-1-yl)acetate 2 (0.260 g, 1.12 mmol) was dissolved in a mixture of aqueous 
NaOH (10% w/v, 10 mL) and THF (10 mL). The reaction mixture was heated under reflux for 1 
hour. The reaction mixture was adjusted to pH 1 by the addition of aqueous HCl (2 M) at 0 °C, 
then extracted into diethyl ether (3 x 100 mL). The combined organic extracts were washed (brine), 
dried (MgSO4) and concentrated in vacuo. Purification by flash column chromatography (0 – 10% 
methanol in DCM) afforded 3 (0.101 g, 44% yield). 1H NMR (400 MHz, (CD3)2SO) 12.61 (1H, 
s), 8.26 (1H, d, J = 7.7 Hz), 7.94 (1H, ddd, J = 8.3, 6.9, 1.4 Hz), 7.90-7.82 (2H, m), 3.95 (2H, s); 
13C NMR (100 MHz, (CD3)2SO) 171.4, 159.5, 141.5, 133.5, 131.6, 129.6, 127.5, 125.9, 125.6, 
38.2; 1H NMR spectroscopic data consistent with literature.17 
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N-(2-Methoxyphenyl)-2-(4-oxo-3,4-dihydrophthalazin-1-yl)acetamide (4). T3P® (50 wt. % 
in DMF, 0.35 mL, 0.59 mmol) and N,N-diisopropylethylamine (0.10 mL, 0.59 mmol) were added 
to a solution of 2-(4-oxo-3,4-dihydrophthalazin-1-yl)acetic acid 3 (40 mg, 0.20 mmol) and o-
anisidine 19 (33 µL, 0.29 mmol) in DMF (1 mL). The reaction mixture was heated to 40 °C over 
2 hours. The reaction mixture was diluted with water (15 mL) and extracted into DCM (3 x 20 
mL). The combined organic extracts were dried (MgSO4) and concentrated in vacuo. The residue 
was dissolved in toluene (10 mL) and concentrated in vacuo. Purification by flash column 
chromatography (50 – 100% ethyl acetate in petroleum ether, 0 – 20% methanol in DCM) afforded 
4 (50 mg, 82% yield). LCMS (ESI+): m/z 332.1 [M + Na]+, rt 1.64 minutes, >99%; 1H NMR (500 
MHz, (CD3)2SO) 12.61 (1H, s), 9.56 (1H, s), 8.27 (1H, d, J = 7.9 Hz), 8.01-7.79 (4H, m), 7.11-
7.00 (2H, m), 6.92-6.83 (1H, m), 4.16 (2H, s), 3.86 (3H, s); 13C NMR (125 MHz, (CD3)2SO) 167.6, 
159.5, 149.6, 142.3, 133.5, 131.5, 129.8, 127.6, 127.2, 125.8, 125.6, 124.6, 121.8, 120.2, 111.2, 
55.7 (1 peak missing); νmax/cm
-1 2905, 1665 (C=O), 1646, 1597, 1539; HRMS (ESI)+: m/z 
calculated for [C17H15N3O3 + H]
+ = 310.1186, observed 310.1175. 
5-(Azepan-1-ylsulfonyl)-2-methoxyaniline (5).14 Hexamethyleneimine (0.212 mL, 1.89 
mmol) was added dropwise at 0 °C to a suspension of sodium hydride (60% in mineral oil, 0.189 
g, 4.72 mmol) in DMF (2 mL). The reaction mixture was stirred at 0 °C over 30 minutes. A solution 
of 4-methoxy-3-(2,2,2-trifluoroacetamido)benzenesulfonyl chloride 21 (0.500 g, 1.57 mmol) in 
DMF (3 mL) was added dropwise at 0 °C to the reaction mixture. The reaction mixture was 
warmed to room temperature and stirred over 3 hours. Ethanol (10 mL) was added dropwise at 0 
°C to the reaction mixture, followed by water (10 mL) and aqueous HCl (37.5% w/v, 10 mL). The 
reaction mixture was heated under reflux for 20 hours. The reaction mixture was concentrated in 
vacuo to remove ethanol, then adjusted to pH 9 by the dropwise addition of aqueous NaOH (10% 
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w/v). The mixture was diluted with ethyl acetate (50 mL), and the resultant aqueous layer 
discarded. The organic layer was washed with water (3 x 50 mL) and brine (50 mL), dried (MgSO4) 
and concentrated in vacuo. Purification by flash column chromatography (20 – 50% ethyl acetate 
in petroleum ether) afforded 5 (0.373 g, 83% yield). LCMS (ESI+): m/z 285.2 [M + H]+, rt 1.85 
minutes, >99%; 1H NMR (400 MHz, CDCl3) 7.17 (1H, dd, J = 8.4, 2.3 Hz), 7.09 (1H, d, J = 2.2 
Hz), 6.81 (1H, d, J = 8.4 Hz), 3.98 (2H, br s), 3.90 (3H, s), 3.23 (4H, t, J = 5.9 Hz), 1.75-1.64 (4H, 
m), 1.62-1.53 (4H, m); 13C NMR (100 MHz, CDCl3) 150.1, 136.7, 131.6, 118.1, 112.7, 109.7, 
55.8, 48.3, 29.3, 27.1; νmax/cm
-1 3484 (N-H), 3379 (N-H), 2932, 2849, 1610, 1577, 1513; HRMS 
(ESI)+: m/z calculated for [C13H20N2O3S + K]
+ = 323.0826, observed 323.0835. 
N-(5-(Azepan-1-ylsulfonyl)-2-methoxyphenyl)acetamide (6). Acetic anhydride (10 µL, 0.11 
mmol) was added to a solution of 5-(azepan-1-ylsulfonyl)-2-methoxyaniline 5 (15 mg, 0.053 
mmol) and pyridine (8.5 µL, 0.11 mmol) in DCM (2 mL). The reaction mixture was stirred over 
90 minutes. The reaction mixture was diluted with water (10 mL) and extracted into DCM (3 x 15 
mL). The combined organic extracts were dried (MgSO4) and concentrated in vacuo. Purification 
by flash column chromatography (50 – 80% ethyl acetate in petroleum ether) afforded 6 (14 mg, 
79% yield). LCMS (ESI+): m/z 327.3 [M + H]+, (ESI-): m/z 325.2 [M - H]-, rt 1.90 minutes, 96%; 
1H NMR (400 MHz, CDCl3) 8.78 (1H, d, J = 1.8 Hz), 7.76 (1H, br s), 7.53 (1H, dd, J = 8.5, 2.3 
Hz), 6.91 (1H, d, J = 8.6 Hz), 3.94 (3H, s), 3.30 (4H, t, J = 6.0 Hz), 2.22 (3H, s), 1.80-1.67 (4H, 
m), 1.65-1.53 (4H, m); 13C NMR (125 MHz, CDCl3) 168.4, 150.4, 132.1, 128.2, 123.5, 118.0, 
109.5, 56.2, 48.5, 29.3, 27.1, 25.0; νmax/cm
-1 3349, 2930, 2855, 1673 (C=O), 1592, 1518; HRMS 
(ESI)+: m/z calculated for [C15H22N2O4S + H]
+ = 327.1373, observed 327.1375. 
2-Amino-4-(azepan-1-ylsulfonyl)phenol (7). Sodium borohydride (28 mg, 0.75 mmol) was 
added portionwise at 0 °C to a suspension of NiCl2·6H2O (59 mg, 0.25 mmol) in methanol (2 mL). 
 30 
The reaction mixture was warmed to room temperature and stirred over 20 minutes. A solution of 
4-(azepan-1-ylsulfonyl)-2-nitrophenol 24 (0.170 g, 0.498 mmol) in methanol (2 mL) was added at 
0 °C to the reaction mixture, followed by further sodium borohydride (94 mg, 2.5 mmol). The 
reaction mixture was warmed to room temperature and stirred over 2 hours. Water (15 mL) was 
added at 0 °C and the reaction mixture filtered through celite. The product was extracted into DCM 
(3 x 25 mL). The combined organic extracts were washed (brine), dried (MgSO4) and concentrated 
in vacuo. Purification by flash column chromatography (20 – 50% ethyl acetate in petroleum ether) 
afforded 7 (83 mg, 62% yield). LCMS (ESI+): m/z 271.2 [M + H]+, (ESI-): m/z 269.2 [M - H]-, rt 
1.71 minutes, >99%; 1H NMR (400 MHz, CD3CN) 7.45 (1H, br s), 7.04 (1H, d, J = 2.3 Hz), 6.94 
(1H, dd, J = 8.2, 2.2 Hz), 6.80 (1H, d, J = 8.3 Hz), 4.26 (2H, br s), 3.18 (4H, t, J = 5.9 Hz), 1.74-
1.60 (4H, m), 1.59-1.50 (4H, m); 13C NMR (100 MHz, CD3CN) 148.0, 137.6, 131.9, 117.8, 114.8, 
113.6, 48.9, 29.8, 27.6; νmax/cm
-1 3397, 3350, 3320, 3285, 2927, 2855, 1593, 1510; HRMS (ESI)-
: m/z calculated for [C12H18N2O3S - H]
- = 269.0965, observed 269.0965. 
3-(Azepan-1-ylsulfonyl)aniline (8). Sodium borohydride (51 mg, 1.4 mmol) was added 
portionwise at 0 °C to a suspension of NiCl2 (59 mg, 0.45 mmol) in methanol (2 mL). The reaction 
mixture was warmed to room temperature and stirred over 30 minutes. 1-((3-
Nitrophenyl)sulfonyl)azepane 27 (0.257 g, 0.904 mmol) was added at 0 °C to the reaction mixture, 
followed by further methanol (4 mL) and sodium borohydride (0.171 g, 4.52 mmol). The reaction 
mixture was warmed to room temperature and stirred over 45 minutes. Water (10 mL) was added 
at 0 °C and the mixture filtered through celite, eluted with methanol (10 mL) and water (15 mL). 
The filtrate was concentrated in vacuo to remove methanol, then extracted into ethyl acetate (3 x 
25 mL). The combined organic extracts were washed (brine), dried (MgSO4) and concentrated in 
vacuo. Purification by flash column chromatography (20 – 50% ethyl acetate in petroleum ether) 
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afforded 8 (0.188 g, 82% yield). LCMS (ESI+): m/z 255.2 [M + H]+, rt 1.77 minutes, >99%; 1H 
NMR (400 MHz, CDCl3) 7.24 (1H, t, J = 7.8 Hz), 7.15-7.10 (1H, m), 7.08 (1H, t, J = 2.0 Hz), 6.81 
(1H, ddd, J = 7.9, 2.3, 0.7 Hz), 3.89 (2H, br s), 3.26 (4H, t, J = 5.9 Hz), 1.77-1.65 (4H, m), 1.63-
1.54 (4H, m); 13C NMR (100 MHz, CDCl3) 147.2, 140.4, 130.0, 118.6, 116.7, 113.0, 48.4, 29.3, 
27.0; νmax/cm
-1 3391 (N-H), 3326 (N-H), 2928, 2851, 1639, 1596; HRMS (ESI)+: m/z calculated 
for [C12H18N2O2S + H]
+ = 255.1162, observed 255.1166. 
N-(3-(Azepan-1-ylsulfonyl)phenyl)acetamide (9). Acetic anhydride (11 µL, 0.12 mmol) was 
added to a solution of 3-(azepan-1-ylsulfonyl)aniline 8 (15 mg, 0.059 mmol) and pyridine (10 µL, 
0.12 mmol) in DCM (2 mL). The reaction mixture was stirred over 5 hours. The reaction mixture 
was diluted with water (10 mL) and extracted into DCM (3 x 15 mL). The combined organic 
extracts were dried (MgSO4) and concentrated in vacuo. Purification by flash column 
chromatography (35 – 70% ethyl acetate in petroleum ether) afforded 9 (15 mg, 86% yield). LCMS 
(ESI+): m/z 297.2 [M + H]+, (ESI-): m/z 295.2 [M - H]-, rt 1.87 minutes, >99%; 1H NMR (500 
MHz, CDCl3) 7.98 (1H, d, J = 7.9 Hz), 7.91 (1H, br s), 7.83-7.78 (1H, m), 7.52-7.47 (1H, m), 7.45 
(1H, t, J = 7.9 Hz), 3.27 (4H, t, J = 6.0 Hz), 2.21 (3H, s), 1.76-1.66 (4H, m), 1.65-1.53 (4H, m); 
13C NMR (125 MHz, CDCl3) 169.0, 139.9, 139.1, 130.0, 123.7, 122.2, 117.9, 48.5, 29.3, 27.0, 
24.7; νmax/cm
-1 3305, 3257, 3192, 3117, 2929, 2851, 1670 (C=O), 1592, 1545; HRMS (ESI)+: m/z 
calculated for [C14H20N2O3S + H]
+ = 297.1267, observed 297.1268. 
1-((4-Methoxyphenyl)sulfonyl)azepane (10). Chlorosulfonic acid (0.25 mL, 3.7 mmol) was 
added dropwise at 0 °C to a mixture of anisole 30 (0.201 mL, 1.85 mmol) and chloroform (5 mL). 
The reaction mixture was warmed to room temperature and stirred over 30 minutes. Water (15 
mL) was added dropwise at 0 °C to the reaction mixture. The mixture was extracted into DCM (3 
x 20 mL). The combined organic extracts were washed (brine), dried (MgSO4) and concentrated 
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in vacuo to afford a crude residue. Hexamethyleneimine (0.141 mL, 1.26 mmol) was added 
dropwise at 0 °C to a suspension of sodium hydride (60% in mineral oil, 0.137 g, 3.43 mmol) in 
DMF (1 mL). The reaction mixture was stirred at 0 °C over 20 minutes. A solution of the crude 
residue in DMF (2 mL) was added dropwise at 0 °C to the reaction mixture. The reaction mixture 
was warmed to room temperature and stirred over 1 hour. Water (15 mL) was added dropwise at 
0 °C to the reaction mixture. The product was extracted into DCM (3 x 20 mL). The combined 
organic extracts were washed (brine), dried (MgSO4) and concentrated in vacuo. The residue was 
dissolved in toluene (5 mL) and concentrated in vacuo. Purification by flash column 
chromatography (0 – 35% ethyl acetate in petroleum ether) afforded 10 (0.243 g, 49% yield). 
LCMS (ESI+): m/z 270.2 [M + H]+, rt 2.15 minutes, >99%; 1H NMR (400 MHz, CDCl3) 7.75-
7.70 (2H, m), 6.99-6.93 (2H, m), 3.86 (3H, s), 3.25 (4H, t, J = 5.9 Hz), 1.75-1.66 (4H, m), 1.62-
1.53 (4H, m); 13C NMR (100 MHz, CDCl3) 162.6, 131.5, 129.1, 114.2, 55.7, 48.3, 29.2, 27.1; 
νmax/cm
-1 2929, 2848, 1595, 1579, 1501; HRMS (ESI)+: m/z calculated for [C13H19NO3S + H]
+ = 
270.1158, observed 270.1153. 
N-(2-Methoxy-5-(N-methylsulfamoyl)phenyl)acetamide (11). Acetic anhydride (18 µL, 0.19 
mmol) was added to a solution of 3-amino-4-methoxy-N-methylbenzenesulfonamide 31a (42 mg, 
0.19 mmol) and pyridine (16 µL, 0.19 mmol) in DCM (2 mL). The reaction mixture was stirred 
over 2 days. The reaction mixture was diluted with water (15 mL) and extracted into DCM (3 x 20 
mL). The combined organic extracts were dried (MgSO4) and concentrated in vacuo. Purification 
by flash column chromatography (50 – 100% ethyl acetate in petroleum ether) afforded 11 (28 mg, 
56% yield). LCMS (ESI+): m/z 259.2 [M + H]+, (ESI-): m/z 257.2 [M - H]-, rt 1.31 minutes, >99%; 
1H NMR (400 MHz, CD3CN) 8.74 (1H, d, J = 2.0 Hz), 8.30 (1H, br s), 7.51 (1H, dd, J = 8.5, 2.2 
Hz), 7.10 (1H, d, J = 8.6 Hz), 5.43-5.27 (1H, m), 3.94 (3H, s), 2.47 (3H, d, J = 5.3 Hz), 2.14 (3H, 
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s); 13C NMR (100 MHz, CD3CN) 170.0, 152.2, 131.6, 129.5, 124.0, 118.7, 111.2, 56.9, 29.5, 24.7; 
νmax/cm
-1 3422 (N-H), 3168, 1672 (C=O), 1594, 1530; HRMS (ESI)+: m/z calculated for 
[C10H14N2O4S + Na]
+ = 281.0566, observed 281.0569. 
N-(3-(Azepan-1-ylsulfonyl)phenyl)-2-(4-oxo-3,4-dihydrophthalazin-1-yl)acetamide (12). 
T3P® (50 wt. % in ethyl acetate, 0.35 mL, 0.59 mmol) and N,N-diisopropylethylamine (0.17 mL, 
0.98 mmol) were added to a solution of 2-(4-oxo-3,4-dihydrophthalazin-1-yl)acetic acid 3 (47 mg, 
0.20 mmol) and 3-(azepan-1-ylsulfonyl)aniline 8 (50 mg, 0.20 mmol) in DMF (2 mL). The 
reaction mixture was heated to 70 °C over 2 hours. The reaction mixture was diluted with ethyl 
acetate (25 mL), washed with water (3 x 25 mL) and brine (25 mL), dried (MgSO4) and 
concentrated in vacuo. Purification by flash column chromatography (50 – 90% ethyl acetate in 
petroleum ether) afforded 12 (40 mg, 45% yield). LCMS (ESI+): m/z 441.3 [M + H]+, (ESI-): m/z 
439.2 [M - H]-, rt 1.82 minutes, 98%; 1H NMR (500 MHz, (CD3)2SO) 12.63 (1H, s), 10.67 (1H, 
s), 8.30-8.25 (1H, m), 8.13 (1H, t, J = 1.8 Hz), 7.98-7.92 (2H, m), 7.86 (1H, ddd, J = 8.1, 5.7, 2.4 
Hz), 7.78 (1H, dq, J = 8.2, 1.0 Hz), 7.54 (1H, t, J = 8.0 Hz), 7.44 (1H, dq, J = 7.8, 0.9 Hz), 4.10 
(2H, s), 3.18 (4H, t, J = 5.9 Hz), 1.66-1.56 (4H, m), 1.53-1.44 (4H, m); 13C NMR (125 MHz, 
(CD3)2SO) 168.1, 159.5, 141.8, 139.7, 139.5, 133.6, 131.6, 130.0, 129.8, 127.6, 125.8, 125.6, 
122.6, 121.2, 116.7, 47.7, 28.5, 26.3 (1 peak missing); νmax/cm
-1 2929, 2852, 1644 (C=O), 1591, 
1541; HRMS (ESI)+: m/z calculated for [C22H24N4O4S + H]
+ = 441.1591, observed 441.1613. 
N-(5-(Azepan-1-ylsulfonyl)-2-methylphenyl)-2-(4-oxo-3,4-dihydrophthalazin-1-
yl)acetamide (13). T3P® (50 wt. % in ethyl acetate, 0.33 mL, 0.56 mmol) and N,N-
diisopropylethylamine (0.16 mL, 0.93 mmol) were added to a solution of 2-(4-oxo-3,4-
dihydrophthalazin-1-yl)acetic acid 3 (44 mg, 0.19 mmol) and 5-(azepan-1-ylsulfonyl)-2-
methylaniline 29 (50 mg, 0.19 mmol) in DMF (2 mL). The reaction mixture was heated to 70 °C 
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over 2 hours. The reaction mixture was diluted with ethyl acetate (25 mL), washed with water (3 
x 25 mL) and brine (25 mL), dried (MgSO4) and concentrated in vacuo. Purification by flash 
column chromatography (50 – 90% ethyl acetate in petroleum ether, 0 – 5% methanol in DCM) 
afforded 13 (42 mg, 50% yield). LCMS (ESI+): m/z 455.3 [M + H]+, (ESI-): m/z 453.2 [M - H]-, 
rt 1.82 minutes, >99%; 1H NMR (500 MHz, (CD3)2SO) 12.64 (1H, s), 9.84 (1H, s), 8.28 (1H, d, J 
= 7.7 Hz), 8.02-7.92 (3H, m), 7.87 (1H, ddd, J = 8.0, 6.7, 1.5 Hz), 7.49-7.41 (2H, m), 4.15 (2H, s), 
3.14 (4H, t, J = 6.0 Hz), 2.33 (3H, s), 1.65-1.53 (4H, m), 1.51-1.42 (4H, m); 13C NMR (125 MHz, 
(CD3)2SO) 168.0, 159.5, 142.0, 136.8, 136.5, 135.8, 133.5, 131.6, 131.3, 129.8, 127.6, 125.9, 
125.5, 122.8, 122.1, 47.7, 28.5, 26.3, 18.0 (1 peak missing); νmax/cm
-1 3177, 3045, 2915, 2853, 
1651 (C=O), 1612, 1600, 1582, 1553; HRMS (ESI)+: m/z calculated for [C23H26N4O4S + H]
+ = 
455.1748, observed 455.1769. 
N-(5-(Azepane-1-carbonyl)-2-methoxyphenyl)-2-(4-oxo-3,4-dihydrophthalazin-1-
yl)acetamide (14). T3P® (50 wt. % in ethyl acetate, 0.12 mL, 0.20 mmol) and N,N-
diisopropylethylamine (58 µL, 0.33 mmol) were added to a solution of 2-(4-oxo-3,4-
dihydrophthalazin-1-yl)acetic acid 3 (14 mg, 0.067 mmol) and (3-amino-4-
methoxyphenyl)(azepan-1-yl)methanone 35 (17 mg, 0.067 mmol) in DMF (1 mL). The reaction 
mixture was heated to 70 °C over 2 hours. The reaction mixture was diluted with ethyl acetate (25 
mL), washed with water (3 x 10 mL) and brine (25 mL), dried (MgSO4) and concentrated in vacuo. 
Purification by flash column chromatography (50 – 100% ethyl acetate in petroleum ether, 0 – 
10% methanol in DCM) afforded 14 (13 mg, 45% yield). LCMS (ESI+): m/z 435.3 [M + H]+, 
(ESI-): m/z 433.3 [M - H]-, rt 1.68 minutes, >99%; 1H NMR (400 MHz, (CD3)2CO) 11.69 (1H, br 
s), 9.01 (1H, br s), 8.39-8.32 (2H, m), 8.04 (1H, d, J = 8.1 Hz), 7.94 (1H, td, J = 7.7, 1.5 Hz), 7.89-
7.82 (1H, m), 7.09 (1H, dd, J = 8.4, 2.0 Hz), 7.04 (1H, d, J = 8.4 Hz), 4.21 (2H, s), 3.91 (3H, s), 
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3.56 (2H, br s), 3.40 (2H, br s), 1.81-1.47 (8H, m); 13C NMR (125 MHz, (CD3)2SO) 169.9, 167.9, 
159.5, 149.7, 142.2, 133.5, 131.5, 129.8, 129.1, 127.6, 126.8, 125.8, 125.5, 122.9, 119.9, 110.8, 
55.9, 49.2, 45.5, 28.9, 27.2, 26.8, 25.8 (1 peak missing); νmax/cm
-1 3191, 2929, 2856, 1674, 1648, 
1618, 1548; HRMS (ESI)+: m/z calculated for [C24H26N4O4 + H]
+ = 435.2027, observed 435.2025. 
N-(5-(Azepan-1-ylsulfonyl)-2-methoxyphenyl)-2-(1H-indol-3-yl)acetamide (15a). T3P® (50 
wt. % in ethyl acetate, 0.15 mL, 0.26 mmol) and N,N-diisopropylethylamine (75 µL, 0.43 mmol) 
were added to a solution of 3-indoleacetic acid (15 mg, 0.086 mmol) and 5-(azepan-1-ylsulfonyl)-
2-methoxyaniline 5 (24 mg, 0.086 mmol) in DMF (1 mL). The reaction mixture was heated to 70 
°C over 4 hours. The reaction mixture was diluted with ethyl acetate (25 mL), washed with water 
(3 x 10 mL) and brine (25 mL), dried (MgSO4) and concentrated in vacuo. Purification by flash 
column chromatography (40 – 80% ethyl acetate in petroleum ether) afforded 15a (8 mg, 21% 
yield). LCMS (ESI+): m/z 442.3 [M + H]+, (ESI-): m/z 440.2 [M - H]-, rt 2.13 minutes, 97%; 1H 
NMR (400 MHz, (CD3)2SO) 10.98 (1H, s), 9.34 (1H, s), 8.50 (1H, d, J = 2.2 Hz), 7.61 (1H, d, J = 
7.9 Hz), 7.45 (1H, dd, J = 8.6, 2.4 Hz), 7.37 (1H, d, J = 8.1 Hz), 7.30 (1H, d, J = 2.3 Hz), 7.18 (1H, 
d, J = 8.8 Hz), 7.09 (1H, ddd, J = 8.1, 7.0, 1.1 Hz), 6.99 (1H, ddd, J = 7.9, 7.0, 1.0 Hz), 3.87 (2H, 
s), 3.85 (3H, s), 3.12 (4H, t, J = 5.9 Hz), 1.65-1.52 (4H, m), 1.51-1.38 (4H, m); 13C NMR (100 
MHz, (CD3)2SO) 170.4, 151.7, 136.2, 130.4, 127.9, 127.2, 124.3, 123.1, 121.2, 118.7, 118.6, 
118.5, 111.5, 111.1, 108.2, 56.3, 47.7, 33.5, 28.5, 26.4; νmax/cm
-1 3345 (br, N-H), 2928, 2856, 1673 
(C=O), 1594, 1524; HRMS (ESI)+: m/z calculated for [C23H27N3O4S + Na]
+ = 464.1614, observed 
464.1615. 
N-(5-(Azepan-1-ylsulfonyl)-2-methoxyphenyl)-2-(5-methoxy-1H-indol-3-yl)acetamide 
(15b). T3P® (50 wt. % in ethyl acetate, 0.31 mL, 0.53 mmol) and N,N-diisopropylethylamine (0.15 
mL, 0.88 mmol) were added to a solution of 5-methoxy-3-indoleacetic acid (36 mg, 0.18 mmol) 
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and 5-(azepan-1-ylsulfonyl)-2-methoxyaniline 5 (50 mg, 0.18 mmol) in DMF (2 mL). The reaction 
mixture was heated to 70 °C over 2 hours. The reaction mixture was diluted with ethyl acetate (100 
mL), washed with water (3 x 100 mL) and brine (100 mL), dried (MgSO4) and concentrated in 
vacuo. Purification by flash column chromatography (30 – 70% ethyl acetate in petroleum ether) 
afforded 15b (32 mg, 38% yield). LCMS (ESI+): m/z 472.3 [M + H]+, (ESI-): m/z 470.2 [M - H]-
, rt 2.09 minutes, 98%; 1H NMR (500 MHz, (CD3)2SO) 10.81 (1H, d, J = 1.6 Hz), 9.29 (1H, s), 
8.51 (1H, d, J = 2.1 Hz), 7.45 (1H, dd, J = 8.7, 2.3 Hz), 7.29-7.24 (2H, m), 7.17 (1H, d, J = 8.8 
Hz), 7.13 (1H, d, J = 2.4 Hz), 6.74 (1H, dd, J = 8.7, 2.4 Hz), 3.84 (3H, s), 3.83 (2H, s), 3.74 (3H, 
s), 3.13 (4H, t, J = 6.0 Hz), 1.64-1.54 (4H, m), 1.51-1.42 (4H, m); 13C NMR (125 MHz, (CD3)2SO) 
170.4, 153.2, 151.6, 131.3, 130.4, 127.8, 127.4, 124.9, 123.0, 118.5, 112.1, 111.2, 111.0, 107.9, 
100.5, 56.2, 55.3, 47.7, 33.6, 28.4, 26.3; νmax/cm
-1 3350 (br, N-H), 2933, 1719, 1675 (C=O), 1593, 
1522; HRMS (ESI)+: m/z calculated for [C24H29N3O5S + H]
+ = 472.1901, observed 472.1890. 
N-(5-(Azepan-1-ylsulfonyl)-2-methoxyphenyl)-3-(1H-indol-3-yl)propanamide (15c). T3P® 
(50 wt. % in ethyl acetate, 0.25 mL, 0.42 mmol) and N,N-diisopropylethylamine (0.12 mL, 0.70 
mmol) were added to a solution of 3-indolepropionic acid (27 mg, 0.14 mmol) and 5-(azepan-1-
ylsulfonyl)-2-methoxyaniline 5 (40 mg, 0.14 mmol) in DMF (2 mL). The reaction mixture was 
heated to 70 °C over 1 hour. The reaction mixture was diluted with ethyl acetate (25 mL), washed 
with water (3 x 25 mL) and brine (25 mL), dried (MgSO4) and concentrated in vacuo. Purification 
by flash column chromatography (30 – 70% ethyl acetate in petroleum ether) afforded 15c (26 mg, 
41% yield). LCMS (ESI+): m/z 456.3 [M + H]+, (ESI-): m/z 454.3 [M - H]-, rt 2.17 minutes, >99%; 
1H NMR (400 MHz, (CD3)2SO) 10.78 (1H, s), 9.37 (1H, s), 8.51 (1H, d, J = 1.9 Hz), 7.57 (1H, d, 
J = 7.8 Hz), 7.47 (1H, dd, J = 8.7, 2.4 Hz), 7.33 (1H, d, J = 8.0 Hz), 7.19 (1H, d, J = 8.7 Hz), 7.14 
(1H, d, J = 2.0 Hz), 7.06 (1H, t, J = 7.5 Hz), 6.97 (1H, t, J = 7.4 Hz), 3.89 (3H, s), 3.16 (4H, t, J = 
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5.9 Hz), 3.01 (2H, t, J = 7.5 Hz), 2.82 (2H, t, J = 7.5 Hz), 1.70-1.56 (4H, m), 1.55-1.41 (4H, m); 
13C NMR (100 MHz, (CD3)2SO) 171.8, 152.0, 136.2, 130.3, 127.8, 127.0, 123.1, 122.3, 120.9, 
119.4, 118.5, 118.2, 113.6, 111.3, 111.0, 56.2, 47.7, 36.8, 28.5, 26.4, 20.7; νmax/cm
-1 3360 (br, N-
H), 2927, 2856, 1674 (C=O), 1594, 1524; HRMS (ESI)+: m/z calculated for [C24H29N3O4S + H]
+ 
= 456.1952, observed 456.1970. 
N-(5-(Azepan-1-ylsulfonyl)-2-methoxyphenyl)-2-(benzofuran-3-yl)acetamide (15d). T3P® 
(50 wt. % in ethyl acetate, 0.31 mL, 0.53 mmol) and N,N-diisopropylethylamine (0.15 mL, 0.88 
mmol) were added to a solution of benzo[b]furan-3-ylacetic acid (31 mg, 0.18 mmol) and 5-
(azepan-1-ylsulfonyl)-2-methoxyaniline 5 (50 mg, 0.18 mmol) in DMF (2 mL). The reaction 
mixture was heated to 70 °C over 90 minutes. The reaction mixture was diluted with ethyl acetate 
(25 mL), washed with water (3 x 25 mL) and brine (25 mL), dried (MgSO4) and concentrated in 
vacuo. Purification by flash column chromatography (30 – 60% ethyl acetate in petroleum ether) 
afforded 15d (50 mg, 64% yield). LCMS (ESI+): m/z 443.3 [M + H]+, (ESI-): m/z 441.3 [M - H]-
, rt 2.24 minutes, >99%; 1H NMR (500 MHz, (CD3)2SO) 9.70 (1H, s), 8.46 (1H, d, J = 2.0 Hz), 
7.92 (1H, s), 7.69 (1H, d, J = 7.6 Hz), 7.57 (1H, d, J = 8.2 Hz), 7.49 (1H, dd, J = 8.5, 2.3 Hz), 7.32 
(1H, td, J = 7.7, 1.1 Hz), 7.27 (1H, t, J = 7.5 Hz), 7.22 (1H, d, J = 8.7 Hz), 3.94 (3H, s), 3.92 (2H, 
s), 3.13 (4H, t, J = 5.9 Hz), 1.64-1.53 (4H, m), 1.51-1.42 (4H, m); 13C NMR (125 MHz, (CD3)2SO) 
169.0, 154.5, 152.1, 143.5, 130.4, 127.8, 127.6, 124.4, 123.4, 122.6, 120.2, 119.3, 114.6, 111.3, 
111.2, 56.3, 47.6, 31.2, 28.4, 26.3; νmax/cm
-1 3353, 2929, 2855, 1680 (C=O), 1593, 1523; HRMS 
(ESI)+: m/z calculated for [C23H26N2O5S + H]
+ = 443.1635, observed 443.1652. 
N-(5-(Azepan-1-ylsulfonyl)-2-methoxyphenyl)-2-(benzo[d]isoxazol-3-yl)acetamide (15e). 
T3P® (50 wt. % in ethyl acetate, 81 µL, 0.14 mmol) and N,N-diisopropylethylamine (39 µL, 0.23 
mmol) were added to a solution of 2-(1,2-benzisoxazol-3-yl)acetic acid (8 mg, 0.05 mmol) and 5-
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(azepan-1-ylsulfonyl)-2-methoxyaniline 5 (13 mg, 0.045 mmol) in DMF (1 mL). The reaction 
mixture was heated to 70 °C over 3 hours. The reaction mixture was diluted with ethyl acetate (25 
mL), washed with water (3 x 15 mL) and brine (25 mL), dried (MgSO4) and concentrated in vacuo. 
Purification by flash column chromatography (30 – 70% ethyl acetate in petroleum ether) followed 
by reverse phase column chromatography (0 – 100% acetonitrile in water (+ 0.1% NH3)) afforded 
15e (11 mg, 55% yield). LCMS (ESI+): m/z 444.3 [M + H]+, (ESI-): m/z 442.2 [M - H]-, rt 2.15 
minutes, >99%; 1H NMR (400 MHz, (CD3)2SO) 10.03 (1H, s), 8.44 (1H, d, J = 1.9 Hz), 7.91 (1H, 
d, J = 8.0 Hz), 7.75 (1H, d, J = 8.5 Hz), 7.66 (1H, t, J = 7.7 Hz), 7.52 (1H, dd, J = 8.6, 2.2 Hz), 
7.41 (1H, t, J = 7.4 Hz), 7.25 (1H, d, J = 8.7 Hz), 4.34 (2H, s), 3.97 (3H, s), 3.13 (4H, t, J = 5.9 
Hz), 1.67-1.52 (4H, m), 1.51-1.39 (4H, m); 13C NMR (100 MHz, (CD3)2SO) 166.8, 162.4, 154.2, 
152.2, 130.4, 127.4, 123.7, 122.6, 121.5, 119.5, 111.3, 109.7, 56.3, 47.6, 32.8, 28.5, 26.3 (2 peaks 
missing); νmax/cm
-1 2923, 2856, 1689 (C=O), 1595, 1527; HRMS (ESI)+: m/z calculated for 
[C22H25N3O5S + H]
+ = 444.1588, observed 444.1592. 
N-(5-(Azepan-1-ylsulfonyl)-2-methoxyphenyl)-2-(1H-benzo[d]imidazol-1-yl)acetamide 
(15f). T3P® (50 wt. % in ethyl acetate, 0.25 mL, 0.42 mmol) and N,N-diisopropylethylamine (0.12 
mL, 0.70 mmol) were added to a solution of 2-(1H-benzimidazol-1-yl)acetic acid (25 mg, 0.14 
mmol) and 5-(azepan-1-ylsulfonyl)-2-methoxyaniline 5 (40 mg, 0.14 mmol) in DMF (2 mL). The 
reaction mixture was heated to 70 °C over 1 hour. The reaction mixture was diluted with ethyl 
acetate (25 mL), washed with water (3 x 25 mL) and brine (25 mL), dried (MgSO4) and 
concentrated in vacuo. Purification by flash column chromatography (50 – 100% ethyl acetate in 
petroleum ether, 0 – 5% methanol in DCM) afforded 15f (33 mg, 53% yield). LCMS (ESI+): m/z 
443.3 [M + H]+, (ESI-): m/z 441.2 [M - H]-, rt 1.62 minutes, >99%; 1H NMR (500 MHz, (CD3)2SO) 
10.00 (1H, s), 8.45 (1H, d, J = 2.2 Hz), 8.23 (1H, s), 7.70-7.65 (1H, m), 7.54 (1H, d, J = 7.8 Hz), 
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7.51 (1H, dd, J = 8.7, 2.3 Hz), 7.29-7.19 (3H, m), 5.31 (2H, s), 3.98 (3H, s), 3.11 (4H, t, J = 5.9 
Hz), 1.62-1.51 (4H, m), 1.49-1.40 (4H, m); 13C NMR (125 MHz, (CD3)2SO) 166.5, 152.0, 145.0, 
143.2, 134.4, 130.4, 127.3, 123.7, 122.4, 121.6, 119.4, 119.1, 111.3, 110.3, 56.4, 47.6, 47.3, 28.4, 
26.3; νmax/cm
-1 2930, 2853, 1694 (C=O), 1596, 1533; HRMS (ESI)+: m/z calculated for 
[C22H26N4O4S + H]
+ = 443.1748, observed 443.1769. 
N-(5-(Azepan-1-ylsulfonyl)-2-methoxyphenyl)-2-(quinolin-4-yl)acetamide (15g). Lithium 
diisopropylamide (2 M in THF/heptane/ethylbenzene, 1.5 mL, 3.0 mmol) was added dropwise 
over 30 minutes at -78 °C to a mixture of 4-methylquinoline 36 (0.33 mL, 2.5 mmol) and THF (5 
mL). The reaction mixture was stirred at -78 °C over 1 hour, then solid CO2 pellets (1 g) were 
added. The reaction mixture was stirred at -78 °C over 10 minutes, then warmed to room 
temperature and stirred over 1 hour. Water (20 mL) was added dropwise at 0 °C, followed by 
aqueous NaOH (10% w/v, 5 mL). The mixture was washed with DCM (3 x 25 mL), then adjusted 
to pH 6 and washed with DCM/methanol (9:1, 3 x 50 mL). The aqueous phase was concentrated 
in vacuo to afford a crude residue. 5-(azepan-1-ylsulfonyl)-2-methoxyaniline 5 (0.140 g, 0.492 
mmol) and DMF (10 mL) were added to the crude residue, followed by T3P® (50 wt. % in ethyl 
acetate, 3.5 mL, 5.9 mmol) and N,N-diisopropylethylamine (1.7 mL, 9.9 mmol). The reaction 
mixture was heated to 70 °C over 40 minutes. The reaction mixture was diluted with ethyl acetate 
(100 mL), washed with water (3 x 100 mL) and brine (100 mL), dried (MgSO4) and concentrated 
in vacuo. Purification by flash column chromatography (50 – 100% ethyl acetate in petroleum 
ether, 0 – 10% methanol in DCM) followed by reverse phase column chromatography (0 – 50% 
acetonitrile in water (+ 0.1% NH3)) afforded 15g (11 mg, 5% yield). LCMS (ESI+): m/z 454.3 [M 
+ H]+, (ESI-): m/z 452.3 [M - H]-, rt 1.70 minutes, >99%; 1H NMR (400 MHz, (CD3)2SO) 9.90 
(1H, s), 8.85 (1H, d, J = 4.3 Hz), 8.42 (1H, d, J = 2.2 Hz), 8.19 (1H, d, J = 8.4 Hz), 8.05 (1H, dd, 
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J = 8.4, 0.7 Hz), 7.77 (1H, ddd, J = 8.4, 6.9, 1.4 Hz), 7.65 (1H, ddd, J = 8.4, 6.9, 1.3 Hz), 7.53-7.46 
(2H, m), 7.24 (1H, d, J = 8.8 Hz), 4.39 (2H, s), 3.97 (3H, s), 3.11 (4H, t, J = 5.9 Hz), 1.63-1.51 
(4H, m), 1.50-1.39 (4H, m); 13C NMR (125 MHz, CDCl3) 167.1, 150.6, 150.5, 148.8, 140.2, 132.2, 
130.6, 130.0, 127.63, 127.58, 127.4, 124.0, 123.7, 122.8, 118.1, 109.6, 56.2, 48.5, 42.1, 29.3, 27.0; 
νmax/cm
-1 3295, 2923, 1663 (C=O), 1593, 1537; HRMS (ESI)+: m/z calculated for [C24H27N3O4S 
+ H]+ = 454.1795, observed  454.1781. 
N-(5-(Azepan-1-ylsulfonyl)-2-methoxyphenyl)-2-(naphthalen-1-yl)acetamide (15h). T3P® 
(50 wt. % in ethyl acetate, 0.31 mL, 0.53 mmol) and N,N-diisopropylethylamine (0.15 mL, 0.88 
mmol) were added to a solution of 1-naphthaleneacetic acid (33 mg, 0.18 mmol) and 5-(azepan-1-
ylsulfonyl)-2-methoxyaniline 5 (50 mg, 0.18 mmol) in DMF (2 mL). The reaction mixture was 
heated to 70 °C over 2 hours. The reaction mixture was diluted with ethyl acetate (25 mL), washed 
with water (3 x 25 mL) and brine (25 mL), dried (MgSO4) and concentrated in vacuo. Purification 
by flash column chromatography (0 – 50% ethyl acetate in petroleum ether) afforded 15h (53 mg, 
67% yield). LCMS (ESI+): m/z 453.3 [M + H]+, (ESI-): m/z 451.3 [M - H]-, rt 2.37 minutes, >99%; 
1H NMR (400 MHz, (CD3)2SO) 9.69 (1H, s), 8.44 (1H, d, J = 2.3 Hz), 8.12 (1H, d, J = 7.9 Hz), 
7.98-7.91 (1H, m), 7.86 (1H, dd, J = 7.2, 2.2 Hz), 7.59-7.44 (5H, m), 7.22 (1H, d, J = 8.8 Hz), 4.30 
(2H, s), 3.94 (3H, s), 3.11 (4H, t, J = 5.9 Hz), 1.62-1.51 (4H, m), 1.49-1.40 (4H, m); 13C NMR 
(125 MHz, CDCl3) 169.0, 150.6, 134.2, 132.2, 132.1, 130.6, 129.0, 128.9, 128.6, 127.9, 127.1, 
126.4, 125.8, 123.9, 123.6, 117.9, 109.4, 56.0, 48.5, 43.1, 29.4, 27.0; νmax/cm
-1 3360, 2925, 2862, 
1675 (C=O), 1592, 1519; HRMS (ESI)+: m/z calculated for [C25H28N2O4S + Na]
+ = 475.1662, 
observed 475.1652. 
N-(5-(Azepan-1-ylsulfonyl)-2-methoxyphenyl)-2-(pyridin-4-yl)acetamide (15i). EDC.HCl 
(83 mg, 0.43 mmol), N,N-diisopropylethylamine (0.15 mL, 0.86 mmol) and DMAP (5 mg, 0.04 
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mmol) were added to a solution of 4-pyridylacetic acid hydrochloride (50 mg, 0.29 mmol) and 5-
(azepan-1-ylsulfonyl)-2-methoxyaniline 5 (98 mg, 0.35 mmol) in DCM (2 mL). The reaction 
mixture was stirred over 90 minutes, then diluted with water (25 mL) and extracted into DCM (3 
x 25 mL). The combined organic extracts were washed (brine), dried (MgSO4) and concentrated 
in vacuo. Purification by flash column chromatography (50 – 100% ethyl acetate in petroleum 
ether, 0 – 5% methanol in DCM) afforded 15i (74 mg, 64% yield). LCMS (ESI+): m/z 404.3 [M 
+ H]+, (ESI-): m/z 402.2 [M - H]-, rt 1.54 minutes, >99%; 1H NMR (400 MHz, (CD3)2SO) 9.73 
(1H, s), 8.54-8.48 (2H, m), 8.45 (1H, d, J = 2.2 Hz), 7.49 (1H, dd, J = 8.6, 2.3 Hz), 7.38-7.31 (2H, 
m), 7.23 (1H, d, J = 8.8 Hz), 3.94 (3H, s), 3.86 (2H, s), 3.14 (4H, t, J = 5.9 Hz), 1.66-1.54 (4H, m), 
1.52-1.41 (4H, m); 13C NMR (125 MHz, CDCl3) 167.2, 150.6, 150.5, 143.1, 132.3, 127.6, 124.7, 
124.0, 118.2, 109.6, 56.3, 48.5, 44.2, 29.3, 27.0; νmax/cm
-1 3300, 2931, 2858, 1658 (C=O), 1596, 
1536; HRMS (ESI)+: m/z calculated for [C20H25N3O4S + Na]
+ = 426.1458, observed 426.1447. 
N-(2-Methoxy-5-(N-methylsulfamoyl)phenyl)-2-(4-oxo-3,4-dihydrophthalazin-1-
yl)acetamide (16a). T3P® (50 wt. % in ethyl acetate, 93 µL, 0.16 mmol) and N,N-
diisopropylethylamine (46 µL, 0.26 mmol) were added to a solution of 2-(4-oxo-3,4-
dihydrophthalazin-1-yl)acetic acid 3 (11 mg, 0.052 mmol) and 3-amino-4-methoxy-N-
methylbenzenesulfonamide 31a (11 mg, 0.052 mmol) in DMF (1 mL). The reaction mixture was 
heated to 70 °C over 5 hours. The reaction mixture was diluted with ethyl acetate (25 mL), washed 
with water (3 x 15 mL) and brine (15 mL), dried (MgSO4) and concentrated in vacuo. Purification 
by flash column chromatography (50 – 100% ethyl acetate in petroleum ether, 0 – 10% methanol 
in DCM) afforded 16a (6 mg, 29% yield). LCMS (ESI+): m/z 403.2 [M + H]+, (ESI-): m/z 401.1 
[M - H]-, rt 1.44 minutes, >99%; 1H NMR (500 MHz, (CD3)2SO) 12.61 (1H, s), 9.83 (1H, s), 8.47 
(1H, d, J = 2.2 Hz), 8.27 (1H, d, J = 7.5 Hz), 8.00-7.92 (2H, m), 7.86 (1H, ddd, J = 8.0, 6.3, 1.9 
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Hz), 7.50 (1H, dd, J = 8.7, 2.3 Hz), 7.31-7.22 (2H, m), 4.21 (2H, s), 3.96 (3H, s), 2.35 (3H, d, J = 
5.0 Hz); 13C NMR (125 MHz, (CD3)2SO) 168.2, 159.5, 152.0, 142.2, 133.5, 131.6, 130.7, 129.8, 
127.6, 127.5, 125.8, 125.6, 123.5, 119.5, 111.1, 56.3, 28.6 (1 peak missing); νmax/cm
-1 3277, 3173, 
3016, 2904, 1660 (C=O), 1594, 1537; HRMS (ESI)+: m/z calculated for [C18H18N4O5S + H]
+ = 
403.1071, observed 403.1064. 
N-(5-(Azocan-1-ylsulfonyl)-2-methoxyphenyl)-2-(4-oxo-3,4-dihydrophthalazin-1-
yl)acetamide (16b). T3P® (50 wt. % in ethyl acetate, 0.24 mL, 0.40 mmol) and N,N-
diisopropylethylamine (0.12 mL, 0.67 mmol) were added to a solution of 2-(4-oxo-3,4-
dihydrophthalazin-1-yl)acetic acid 3 (32 mg, 0.13 mmol) and 5-(azocan-1-ylsulfonyl)-2-
methoxyaniline 31b (40 mg, 0.13 mmol) in DMF (2 mL). The reaction mixture was heated to 70 
°C over 2 hours. The reaction mixture was diluted with ethyl acetate (25 mL), washed with water 
(3 x 25 mL) and brine (25 mL), dried (MgSO4) and concentrated in vacuo. Purification by flash 
column chromatography (50 – 100% ethyl acetate in petroleum ether, 0 – 5% methanol in DCM) 
afforded 16b (24 mg, 37% yield). LCMS (ESI+): m/z 485.3 [M + H]+, (ESI-): m/z 483.2 [M - H]-
, rt 1.94 minutes, >99%; 1H NMR (500 MHz, (CD3)2SO) 12.62 (1H, s), 9.86 (1H, s), 8.45 (1H, d, 
J = 2.2 Hz), 8.30-8.25 (1H, m), 7.98-7.92 (2H, m), 7.89-7.83 (1H, m), 7.48 (1H, dd, J = 8.6, 2.3 
Hz), 7.24 (1H, d, J = 8.8 Hz), 4.21 (2H, s), 3.97 (3H, s), 3.01 (4H, t, J = 5.8 Hz), 1.67-1.44 (10H, 
m); 13C NMR (125 MHz, (CD3)2SO) 168.4, 159.5, 152.1, 142.1, 133.5, 131.6, 129.8, 129.5, 127.7, 
127.6, 125.9, 125.5, 123.5, 119.2, 111.2, 56.3, 48.0, 27.2, 26.2, 24.6 (1 peak missing); νmax/cm
-1 
3307, 2923, 1693, 1644 (C=O), 1596, 1530; HRMS (ESI)+: m/z calculated for [C24H28N4O5S + 
H]+ = 485.1853, observed 485.1848. 
N-(2-Methoxy-5-(piperidin-1-ylsulfonyl)phenyl)-2-(4-oxo-3,4-dihydrophthalazin-1-
yl)acetamide (16c). T3P® (50 wt. % in ethyl acetate, 0.14 mL, 0.23 mmol) and N,N-
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diisopropylethylamine (66 µL, 0.38 mmol) were added to a solution of 2-(4-oxo-3,4-
dihydrophthalazin-1-yl)acetic acid 3 (16 mg, 0.076 mmol) and 2-methoxy-5-(piperidin-1-
ylsulfonyl)aniline 31c (21 mg, 0.076 mmol) in DMF (1 mL). The reaction mixture was heated to 
70 °C over 2 hours. The reaction mixture was diluted with ethyl acetate (25 mL), washed with 
water (3 x 10 mL) and brine (25 mL), dried (MgSO4) and concentrated in vacuo. Purification by 
flash column chromatography (50 – 100% ethyl acetate in petroleum ether, 0 – 10% methanol in 
DCM) afforded 16c (14 mg, 40% yield). LCMS (ESI+): m/z 457.3 [M + H]+, (ESI-): m/z 455.2 
[M - H]-, rt 1.76 minutes, 98%; 1H NMR (500 MHz, (CD3)2SO) 12.62 (1H, s), 9.88 (1H, s), 8.39 
(1H, d, J = 2.2 Hz), 8.28 (1H, d, J = 7.9 Hz), 7.99-7.92 (2H, m), 7.86 (1H, ddd, J = 8.0, 5.7, 2.5 
Hz), 7.45 (1H, dd, J = 8.6, 2.3 Hz), 7.28 (1H, d, J = 8.7 Hz), 4.22 (2H, s), 3.98 (3H, s), 2.81 (4H, 
t, J = 5.2 Hz), 1.50 (4H, quin, J = 5.7 Hz), 1.39-1.28 (2H, m); 13C NMR (125 MHz, (CD3)2SO) 
168.4, 159.5, 152.4, 142.1, 133.5, 131.6, 129.8, 127.59, 127.56, 126.7, 125.9, 125.5, 124.3, 119.9, 
111.2, 56.4, 46.5, 24.6, 22.8 (1 peak missing); νmax/cm
-1 3176, 3057, 2923, 1674, 1646 (C=O), 
1594, 1542; HRMS (ESI)+: m/z calculated for [C22H24N4O5S + H]
+ = 457.1540, observed 
457.1537. 
N-(2-Methoxy-5-((4-methylpiperazin-1-yl)sulfonyl)phenyl)-2-(4-oxo-3,4-
dihydrophthalazin-1-yl)acetamide (16d). T3P® (50 wt. % in ethyl acetate, 0.24 mL, 0.41 mmol) 
and N,N-diisopropylethylamine (0.12 mL, 0.68 mmol) were added to a solution of 2-(4-oxo-3,4-
dihydrophthalazin-1-yl)acetic acid 3 (32 mg, 0.14 mmol) and 2-methoxy-5-((4-methylpiperazin-
1-yl)sulfonyl)aniline 31d (40 mg, 0.14 mmol) in DMF (2 mL). The reaction mixture was heated 
to 70 °C over 2 hours. The reaction mixture was diluted with ethyl acetate (25 mL), washed with 
water (3 x 25 mL) and brine (25 mL), dried (MgSO4) and concentrated in vacuo. Purification by 
flash column chromatography (50 – 100% ethyl acetate in petroleum ether, 0 - 10% methanol in 
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DCM) followed by reverse phase column chromatography (0 – 30% acetonitrile in water (+ 0.1% 
NH3)) afforded 16d (10 mg, 16% yield). LCMS (ESI+): m/z 472.3 [M + H]
+, (ESI-): m/z 470.2 
[M - H]-, rt 1.23 minutes, >99%; 1H NMR (500 MHz, (CD3)2SO) 12.62 (1H, s), 9.91 (1H, s), 8.40 
(1H, d, J = 2.2 Hz), 8.30-8.25 (1H, m), 7.99-7.92 (2H, m), 7.86 (1H, ddd, J = 8.0, 5.8, 2.4 Hz), 
7.46 (1H, dd, J = 8.6, 2.3 Hz), 7.30 (1H, d, J = 8.7 Hz), 4.22 (2H, s), 3.99 (3H, s), 2.81 (4H, br s), 
2.38-2.28 (4H, m), 2.10 (3H, s); 13C NMR (125 MHz, (CD3)2SO) 168.4, 159.4, 152.6, 142.1, 133.5, 
131.6, 129.8, 127.62, 127.56, 126.0, 125.8, 125.5, 124.5, 120.0, 111.3, 56.4, 53.5, 45.7, 45.2 (1 
peak missing); νmax/cm
-1 3376, 2922, 1684, 1655 (C=O), 1594, 1533; HRMS (ESI)+: m/z 
calculated for [C22H25N5O5S + H]
+ = 472.1649, observed 472.1662. 
N-(2-Methoxy-5-(morpholinosulfonyl)phenyl)-2-(4-oxo-3,4-dihydrophthalazin-1-
yl)acetamide (16e). T3P® (50 wt. % in ethyl acetate, 0.26 mL, 0.44 mmol) and N,N-
diisopropylethylamine (0.13 mL, 0.73 mmol) were added to a solution of 2-(4-oxo-3,4-
dihydrophthalazin-1-yl)acetic acid 3 (35 mg, 0.15 mmol) and 2-methoxy-5-
(morpholinosulfonyl)aniline 31e (40 mg, 0.15 mmol) in DMF (2 mL). The reaction mixture was 
heated to 70 °C over 2 hours. The reaction mixture was diluted with ethyl acetate (25 mL), washed 
with water (3 x 25 mL) and brine (25 mL), dried (MgSO4) and concentrated in vacuo. Purification 
by flash column chromatography (50 – 100% ethyl acetate in petroleum ether, 0 - 10% methanol 
in DCM) followed by reverse phase column chromatography (0 – 60% acetonitrile in water (+ 
0.1% NH3)) afforded 16e (7 mg, 10% yield). LCMS (ESI+): m/z 459.3 [M + H]
+, (ESI-): m/z 457.3 
[M - H]-, rt 1.55 minutes, >99%; 1H NMR (400 MHz, (CD3)2SO) 12.62 (1H, s), 9.93 (1H, s), 8.41 
(1H, d, J = 2.0 Hz), 8.27 (1H, d, J = 7.8 Hz), 8.01-7.91 (2H, m), 7.86 (1H, ddd, J = 8.0, 5.7, 2.5 
Hz), 7.47 (1H, dd, J = 8.7, 2.2 Hz), 7.31 (1H, d, J = 8.7 Hz), 4.23 (2H, s), 3.99 (3H, s), 3.59 (4H, 
t, J = 4.5 Hz), 2.79 (4H, t, J = 4.4 Hz); 13C NMR (100 MHz, (CD3)2SO) 168.5, 159.5, 152.7, 142.1, 
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133.6, 131.6, 129.8, 127.7, 127.6, 125.9, 125.6, 125.5, 124.6, 120.1, 111.4, 65.2, 56.4, 45.9 (1 peak 
missing); νmax/cm
-1 3175, 3027, 2924, 2854, 1672, 1646 (C=O), 1593, 1538; HRMS (ESI)+: m/z 
calculated for [C21H22N4O6S + Na]
+ = 481.1152, observed 481.1143. 
N-(2-Methoxy-5-(thiomorpholinosulfonyl)phenyl)-2-(4-oxo-3,4-dihydrophthalazin-1-
yl)acetamide (16f). T3P® (50 wt. % in ethyl acetate, 0.24 mL, 0.40 mmol) and N,N-
diisopropylethylamine (0.12 mL, 0.67 mmol) were added to a solution of 2-(4-oxo-3,4-
dihydrophthalazin-1-yl)acetic acid 3 (32 mg, 0.13 mmol) and 2-methoxy-5-
(thiomorpholinosulfonyl)aniline 31f (40 mg, 0.13 mmol) in DMF (2 mL). The reaction mixture 
was heated to 70 °C over 2 hours. The reaction mixture was diluted with ethyl acetate (25 mL), 
washed with water (3 x 25 mL) and brine (25 mL), dried (MgSO4) and concentrated in vacuo. 
Purification by flash column chromatography (50 – 100% ethyl acetate in petroleum ether, 0 – 
10% methanol in DCM) afforded 16f (23 mg, 36% yield). LCMS (ESI+): m/z 475.2 [M + H]+, 
(ESI-): m/z 473.2 [M - H]-, rt 1.72 minutes, >99%; 1H NMR (500 MHz, (CD3)2SO) 12.62 (1H, s), 
9.92 (1H, s), 8.41 (1H, d, J = 2.3 Hz), 8.27 (1H, d, J = 7.9 Hz), 8.00-7.92 (2H, m), 7.86 (1H, ddd, 
J = 8.0, 5.8, 2.3 Hz), 7.47 (1H, dd, J = 8.7, 2.3 Hz), 7.29 (1H, d, J = 8.7 Hz), 4.23 (2H, s), 3.99 
(3H, s), 3.13 (4H, t, J = 4.7 Hz), 2.63 (4H, t, J = 5.1 Hz); 13C NMR (125 MHz, (CD3)2SO) 168.4, 
159.5, 152.6, 142.1, 133.6, 131.6, 129.8, 127.8, 127.6, 127.2, 125.9, 125.6, 124.2, 119.6, 111.4, 
56.4, 47.8, 26.3 (1 peak missing); νmax/cm
-1 3391, 2929, 2849, 1674, 1645, 1607, 1516; HRMS 
(ESI)+: m/z calculated for [C21H22N4O5S2 + H]
+ = 475.1104, observed 475.1104. 
N-(5-((1,1-Dioxidothiomorpholino)sulfonyl)-2-methoxyphenyl)-2-(4-oxo-3,4-
dihydrophthalazin-1-yl)acetamide (16g). T3P® (50 wt. % in ethyl acetate, 0.67 mL, 1.1 mmol) 
and N,N-diisopropylethylamine (0.33 mL, 1.9 mmol) were added to a solution of 2-(4-oxo-3,4-
dihydrophthalazin-1-yl)acetic acid 3 (89 mg, 0.38 mmol) and 4-((3-amino-4-
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methoxyphenyl)sulfonyl)thiomorpholine 1,1-dioxide 31g (0.120 g, 0.375 mmol) in DMF (2 mL). 
The reaction mixture was heated to 70 °C over 1 hour. The reaction mixture was diluted with ethyl 
acetate (25 mL), washed with water (3 x 25 mL) and brine (25 mL), dried (MgSO4) and 
concentrated in vacuo. Purification by flash column chromatography (50 – 100% ethyl acetate in 
petroleum ether, 0 – 20% methanol in DCM) followed by reverse phase column chromatography 
(0 – 60% acetonitrile in water (+ 0.1% NH3)) afforded 16g (55 mg, 28% yield). LCMS (ESI+): 
m/z 507.2 [M + H]+, (ESI-): m/z 505.2 [M - H]-, rt 1.61 minutes, 97%; 1H NMR (500 MHz, 
(CD3)2SO) 12.62 (1H, s), 9.96 (1H, s), 8.47 (1H, s), 8.27 (1H, d, J = 7.8 Hz), 8.02-7.82 (3H, m), 
7.55 (1H, d, J = 8.8 Hz), 7.32 (1H, d, J = 8.7 Hz), 4.23 (2H, s), 4.00 (3H, s), 3.27-3.19 (4H, m) (1 
peak suspected to be obscured by H2O signal); 
13C NMR (125 MHz, (CD3)2SO) 168.6, 159.5, 
152.9, 142.1, 133.6, 131.6, 129.8, 128.0, 127.6, 126.8, 125.9, 125.6, 124.2, 119.5, 111.7, 56.5, 
49.9, 45.1 (1 peak missing); νmax/cm
-1 3403, 3001, 2933, 1663 (C=O), 1597, 1525; HRMS (ESI)-
: m/z calculated for [C21H22N4O7S2 - H]
- = 505.0857, observed 505.0851. 
N-(2-Methoxy-5-(N-phenylsulfamoyl)phenyl)-2-(4-oxo-3,4-dihydrophthalazin-1-
yl)acetamide (16h). T3P® (50 wt. % in ethyl acetate, 0.16 mL, 0.27 mmol) and N,N-
diisopropylethylamine (79 µL, 0.45 mmol) were added to a solution of 2-(4-oxo-3,4-
dihydrophthalazin-1-yl)acetic acid 3 (19 mg, 0.090 mmol) and 3-amino-4-methoxy-N-
phenylbenzenesulfonamide 31h (25 mg, 0.090 mmol) in DMF (1 mL). The reaction mixture was 
heated to 70 °C over 2 hours. The reaction mixture was diluted with ethyl acetate (25 mL), washed 
with water (3 x 10 mL) and brine (25 mL), dried (MgSO4) and concentrated in vacuo. Purification 
by flash column chromatography (50 – 100% ethyl acetate in petroleum ether, 0 – 10% methanol 
in DCM) afforded 16h (14 mg, 33% yield). LCMS (ESI+): m/z 465.2 [M + H]+, (ESI-): m/z 463.2 
[M - H]-, rt 1.71 minutes, 98%; 1H NMR (500 MHz, (CD3)2SO) 12.61 (1H, s), 10.17 (1H, s), 9.78 
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(1H, s), 8.55 (1H, d, J = 2.2 Hz), 8.31-8.25 (1H, m), 7.98-7.91 (2H, m), 7.90-7.84 (1H, m), 7.47 
(1H, dd, J = 8.7, 2.4 Hz), 7.22-7.14 (3H, m), 7.07-7.03 (2H, m), 7.00-6.94 (1H, m), 4.20 (2H, s), 
3.91 (3H, s); 13C NMR (125 MHz, (CD3)2SO) 168.2, 159.4, 152.2, 142.1, 137.9, 133.5, 131.6, 
131.0, 129.8, 129.1, 127.6, 127.5, 125.8, 125.6, 123.7, 123.6, 119.6, 119.3, 111.0, 56.3 (1 peak 
missing); νmax/cm
-1 3175, 3016, 1674, 1647 (C=O), 1592, 1538; HRMS (ESI)+: m/z calculated for 
[C23H20N4O5S + H]
+ = 465.1227, observed 465.1223. 
N-(5-(N-Benzylsulfamoyl)-2-methoxyphenyl)-2-(4-oxo-3,4-dihydrophthalazin-1-
yl)acetamide (16i). T3P® (50 wt. % in ethyl acetate, 0.26 mL, 0.43 mmol) and N,N-
diisopropylethylamine (0.12 mL, 0.71 mmol) were added to a solution of 2-(4-oxo-3,4-
dihydrophthalazin-1-yl)acetic acid 3 (30 mg, 0.14 mmol) and 3-amino-N-benzyl-4-
methoxybenzenesulfonamide 31i (45 mg, 0.14 mmol) in DMF (2 mL). The reaction mixture was 
heated to 70 °C over 2 hours. The reaction mixture was diluted with ethyl acetate (25 mL), washed 
with water (3 x 25 mL) and brine (25 mL), dried (MgSO4) and concentrated in vacuo. Purification 
by flash column chromatography (50 – 100% ethyl acetate in petroleum ether, 0 – 8% methanol in 
DCM) afforded 16i (25 mg, 37% yield). LCMS (ESI+): m/z 479.3 [M + H]+, (ESI-): m/z 477.2 [M 
- H]-, rt 1.74 minutes, >99%; 1H NMR (500 MHz, (CD3)2SO) 12.62 (1H, s), 9.81 (1H, s), 8.51 
(1H, d, J = 2.2 Hz), 8.27 (1H, d, J = 7.8 Hz), 8.03-7.92 (3H, m), 7.86 (1H, ddd, J = 8.0, 6.6, 1.6 
Hz), 7.53 (1H, dd, J = 8.6, 2.3 Hz), 7.28-7.17 (6H, m), 4.22 (2H, s), 3.96 (3H, s), 3.89 (2H, d, J = 
6.5 Hz); 13C NMR (125 MHz, (CD3)2SO) 168.1, 159.5, 152.0, 142.2, 137.7, 133.5, 132.1, 131.6, 
129.8, 128.2, 127.6, 127.53, 127.49, 127.1, 125.8, 125.6, 123.4, 119.4, 111.1, 56.3, 46.1 (1 peak 
missing); νmax/cm
-1 3287, 3176, 3026, 1672, 1647 (C=O), 1593, 1538; HRMS (ESI)+: m/z 
calculated for [C24H22N4O5S + H]
+ = 479.1384, observed 479.1381. 
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N-(5-((3,4-Dihydroisoquinolin-2(1H)-yl)sulfonyl)-2-methoxyphenyl)-2-(4-oxo-3,4-
dihydrophthalazin-1-yl)acetamide (16j). T3P® (50 wt. % in ethyl acetate, 0.28 mL, 0.47 mmol) 
and N,N-diisopropylethylamine (0.14 mL, 0.79 mmol) were added to a solution of 2-(4-oxo-3,4-
dihydrophthalazin-1-yl)acetic acid 3 (37 mg, 0.16 mmol) and 5-((3,4-dihydroisoquinolin-2(1H)-
yl)sulfonyl)-2-methoxyaniline 31j (50 mg, 0.16 mmol) in DMF (2 mL). The reaction mixture was 
heated to 70 °C over 1 hour. The reaction mixture was diluted with ethyl acetate (25 mL), washed 
with water (3 x 25 mL) and brine (25 mL), dried (MgSO4) and concentrated in vacuo. Purification 
by flash column chromatography (50 – 100% ethyl acetate in petroleum ether, 0 – 5% methanol in 
DCM) afforded 16j (35 mg, 43% yield). LCMS (ESI-): m/z 503.3 [M - H]-, rt 1.90 minutes, 98%; 
1H NMR (500 MHz, (CD3)2SO) 12.62 (1H, s), 9.89 (1H, s), 8.50 (1H, d, J = 2.2 Hz), 8.28 (1H, d, 
J = 7.9 Hz), 7.99-7.92 (2H, m), 7.86 (1H, ddd, J = 8.0, 5.9, 2.3 Hz), 7.56 (1H, dd, J = 8.6, 2.3 Hz), 
7.28 (1H, d, J = 8.7 Hz), 7.17-7.05 (4H, m), 4.22 (2H, s), 4.11 (2H, s), 3.97 (3H, s), 3.22 (2H, t, J 
= 6.0 Hz), 2.83 (2H, t, J = 5.8 Hz); 13C NMR (125 MHz, (CD3)2SO) 168.4, 159.5, 152.5, 142.1, 
133.5, 133.0, 131.6, 131.5, 129.8, 128.6, 127.7, 127.6, 126.9, 126.6, 126.4, 126.1, 125.8, 125.6, 
124.4, 119.9, 111.4, 56.4, 47.2, 43.6, 28.0 (1 peak missing); νmax/cm
-1 3354, 2929, 2853, 1679 
(C=O), 1592, 1523; HRMS (ESI)+: m/z calculated for [C26H24N4O5S + H]
+ = 505.1540, observed 
505.1534. 
N-(5-((6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)sulfonyl)-2-methoxyphenyl)-2-(4-
oxo-3,4-dihydrophthalazin-1-yl)acetamide (16k). T3P® (50 wt. % in ethyl acetate, 0.38 mL, 0.63 
mmol) and N,N-diisopropylethylamine (0.18 mL, 1.1 mmol) were added to a solution of 2-(4-oxo-
3,4-dihydrophthalazin-1-yl)acetic acid 3 (50 mg, 0.21 mmol) and 5-((6,7-dimethoxy-3,4-
dihydroisoquinolin-2(1H)-yl)sulfonyl)-2-methoxyaniline 31k (80 mg, 0.21 mmol) in DMF (2 
mL). The reaction mixture was heated to 70 °C over 1 hour. The reaction mixture was diluted with 
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ethyl acetate (25 mL), washed with water (3 x 25 mL) and brine (25 mL), dried (MgSO4) and 
concentrated in vacuo. Purification by flash column chromatography (50 – 100% ethyl acetate in 
petroleum ether, 0 – 7% methanol in DCM) followed by reverse phase column chromatography (0 
– 50% acetonitrile in water (+ 0.1% NH3)) afforded 16k (48 mg, 40% yield). LCMS (ESI+): m/z 
565.4 [M + H]+, (ESI-): m/z 563.2 [M - H]-, rt 1.78 minutes, >99%; 1H NMR (500 MHz, (CD3)2SO) 
12.62 (1H, s), 9.89 (1H, s), 8.50 (1H, d, J = 2.2 Hz), 8.28 (1H, d, J = 7.7 Hz), 7.99-7.92 (2H, m), 
7.86 (1H, ddd, J = 8.0, 6.0, 2.1 Hz), 7.54 (1H, dd, J = 8.6, 2.3 Hz), 7.28 (1H, d, J = 8.9 Hz), 6.71 
(1H, s), 6.65 (1H, s), 4.22 (2H, s), 4.01 (2H, s), 3.97 (3H, s), 3.67 (3H, s), 3.65 (3H, s), 3.18 (2H, 
t, J = 5.9 Hz), 2.74 (2H, t, J = 5.8 Hz); 13C NMR (125 MHz, (CD3)2SO) 168.4, 159.5, 152.5, 147.5, 
147.3, 142.1, 133.5, 131.6, 129.8, 127.7, 127.6, 127.0, 125.8, 125.6, 124.7, 124.4, 123.1, 119.8, 
111.7, 111.3, 109.8, 56.4, 55.5, 55.4, 46.9, 43.7, 27.7 (1 peak missing); νmax/cm
-1 3299, 3010, 2938, 
2837, 1695, 1641 (C=O), 1596, 1520; HRMS (ESI)+: m/z calculated for [C28H28N4O7S + Na]
+ = 
587.1571, observed 587.1543. 
N-(2-Methoxy-5-((1,2,4,5-tetrahydro-3H-benzo[d]azepin-3-yl)sulfonyl)phenyl)-2-(4-oxo-
3,4-dihydrophthalazin-1-yl)acetamide (16l). T3P® (50 wt. % in ethyl acetate, 0.38 mL, 0.63 
mmol) and N,N-diisopropylethylamine (0.18 mL, 1.1 mmol) were added to a solution of 2-(4-oxo-
3,4-dihydrophthalazin-1-yl)acetic acid 3 (50 mg, 0.21 mmol) and 2-methoxy-5-((1,2,4,5-
tetrahydro-3H-benzo[d]azepin-3-yl)sulfonyl)aniline 31l (70 mg, 0.21 mmol) in DMF (2 mL). The 
reaction mixture was heated to 70 °C over 2 hours. The reaction mixture was diluted with ethyl 
acetate (25 mL), washed with water (3 x 25 mL) and brine (25 mL), dried (MgSO4) and 
concentrated in vacuo. Purification by flash column chromatography (50 – 80% ethyl acetate in 
petroleum ether, 0 – 5% methanol in DCM) followed by reverse phase column chromatography (0 
– 100% acetonitrile in water (+ 0.1% NH3)) afforded 16l (20 mg, 18% yield). LCMS (ESI+): m/z 
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519.3 [M + H]+, (ESI-): m/z 517.2 [M - H]-, rt 2.06 minutes, >99%; 1H NMR (500 MHz, (CD3)2SO) 
12.61 (1H, s), 9.85 (1H, s), 8.42 (1H, d, J = 2.1 Hz), 8.27 (1H, d, J = 7.8 Hz), 7.97-7.90 (2H, m), 
7.89-7.83 (1H, m), 7.48 (1H, dd, J = 8.7, 2.3 Hz), 7.23 (1H, d, J = 8.8 Hz), 7.12-7.04 (4H, m), 4.19 
(2H, s), 3.94 (3H, s), 3.18-3.04 (4H, m), 2.96-2.83 (4H, m); 13C NMR (125 MHz, (CD3)2SO) 168.4, 
159.4, 152.3, 142.1, 140.4, 133.5, 131.6, 129.8, 129.1, 128.7, 127.7, 127.6, 126.5, 125.9, 125.5, 
123.9, 119.3, 111.3, 56.3, 48.1, 35.5 (1 peak missing); νmax/cm
-1 3302, 3173, 3011, 2906, 1687, 
1650 (C=O), 1595, 1530; HRMS (ESI)-: m/z calculated for [C27H26N4O5S - H]
- = 517.1551, 
observed 517.1549. 
N-(2-Methoxy-5-((7-methoxy-1,2,4,5-tetrahydro-3H-benzo[d]azepin-3-
yl)sulfonyl)phenyl)-2-(4-oxo-3,4-dihydrophthalazin-1-yl)acetamide (16m). T3P® (50 wt. % in 
ethyl acetate, 0.50 mL, 0.84 mmol) and N,N-diisopropylethylamine (0.24 mL, 1.4 mmol) were 
added to a solution of 2-(4-oxo-3,4-dihydrophthalazin-1-yl)acetic acid 3 (66 mg, 0.28 mmol) and 
2-methoxy-5-((7-methoxy-1,2,4,5-tetrahydro-3H-benzo[d]azepin-3-yl)sulfonyl)aniline 31m 
(0.101 g, 0.279 mmol) in DMF (2 mL). The reaction mixture was heated to 70 °C over 1 hour. The 
reaction mixture was diluted with ethyl acetate (25 mL), washed with water (3 x 25 mL) and brine 
(25 mL), dried (MgSO4) and concentrated in vacuo. Purification by flash column chromatography 
(50 – 100% ethyl acetate in petroleum ether, 0 – 7% methanol in DCM) afforded 16m (48 mg, 
30% yield). LCMS (ESI+): m/z 549.4 [M + H]+, (ESI-): m/z 547.3 [M - H]-, rt 1.96 minutes, 96%; 
1H NMR (500 MHz, (CD3)2SO) 12.61 (1H, s), 9.85 (1H, s), 8.41 (1H, d, J = 2.1 Hz), 8.27 (1H, d, 
J = 7.9 Hz), 7.97-7.90 (2H, m), 7.89-7.83 (1H, m), 7.47 (1H, dd, J = 8.7, 2.3 Hz), 7.22 (1H, d, J = 
8.8 Hz), 6.98 (1H, d, J = 8.2 Hz), 6.67 (1H, d, J = 2.6 Hz), 6.62 (1H, dd, J = 8.2, 2.8 Hz), 4.20 (2H, 
s), 3.94 (3H, s), 3.66 (3H, s), 3.15-3.02 (4H, m), 2.91-2.76 (4H, m); 13C NMR (125 MHz, 
(CD3)2SO) 168.4, 159.5, 157.8, 152.3, 142.1, 141.7, 133.6, 132.4, 131.6, 130.2, 129.8, 128.7, 
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127.7, 127.6, 125.9, 125.5, 123.9, 119.3, 115.0, 111.3, 111.2, 56.3, 55.0, 48.6, 48.1, 35.7, 34.7 (1 
peak missing); νmax/cm
-1 3308, 2913, 1691, 1642 (C=O), 1595, 1529; HRMS (ESI)+: m/z 
calculated for [C28H28N4O6S + Na]
+ = 571.1622, observed 571.1615. 
N-(2-Methoxy-5-((1,2,4,5-tetrahydro-3H-1,5-methanobenzo[d]azepin-3-
yl)sulfonyl)phenyl)-2-(4-oxo-3,4-dihydrophthalazin-1-yl)acetamide (16n). T3P® (50 wt. % in 
ethyl acetate, 0.26 mL, 0.43 mmol) and N,N-diisopropylethylamine (0.13 mL, 0.72 mmol) were 
added to a solution of 2-(4-oxo-3,4-dihydrophthalazin-1-yl)acetic acid 3 (34 mg, 0.14 mmol) and 
2-methoxy-5-((1,2,4,5-tetrahydro-3H-1,5-methanobenzo[d]azepin-3-yl)sulfonyl)aniline 31n (55 
mg, 0.14 mmol) in DMF (2 mL). The reaction mixture was heated to 70 °C over 45 minutes. The 
reaction mixture was diluted with ethyl acetate (25 mL), washed with water (3 x 25 mL) and brine 
(25 mL), dried (MgSO4) and concentrated in vacuo. Purification by flash column chromatography 
(50 – 80% ethyl acetate in petroleum ether, 0 – 5% methanol in DCM) followed by reverse phase 
column chromatography (0 – 50% acetonitrile in water (+ 0.1% NH3)) afforded 16n (26 mg, 33% 
yield). LCMS (ESI+): m/z 531.3 [M + H]+, (ESI-): m/z 529.3 [M - H]-, rt 1.98 minutes, 96%; 1H 
NMR (500 MHz, (CD3)2SO) 12.64 (1H, s), 9.82 (1H, s), 8.28 (1H, d, J = 7.9 Hz), 8.22 (1H, d, J = 
1.6 Hz), 8.01-7.92 (2H, m), 7.87 (1H, ddd, J = 8.0, 6.3, 1.9 Hz), 7.22-7.06 (6H, m), 4.23 (2H, s), 
3.97 (3H, s), 3.40 (2H, d, J = 10.6 Hz), 3.18-3.12 (2H, m), 2.80 (2H, d, J = 10.8 Hz), 2.11-2.01 
(1H, m), 1.51 (1H, d, J = 10.9 Hz); 13C NMR (125 MHz, (CD3)2SO) 168.2, 159.5, 152.1, 144.3, 
142.1, 133.5, 131.6, 129.8, 128.1, 127.6, 127.5, 126.9, 125.9, 125.6, 123.6, 122.4, 119.6, 111.0, 
56.3, 49.2, 41.2 (2 peaks missing); νmax/cm
-1 3177, 3020, 2937, 2908, 2851, 1673, 1646 (C=O), 
1597, 1540; HRMS (ESI)+: m/z calculated for [C28H26N4O5S + Na]
+ = 553.1516, observed 
553.1517. 
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Expression and Purification of Mycobacterium tuberculosis fumarate hydratase. A single 
freshly transformed Escherichia coli strain BL21 (DE3) colony was transferred to LB media (20 
mL) with ampicillin (100 µg mL-1) and incubated overnight (37 °C, 200 rpm). The starter culture 
was used to inoculate 2 flasks, each containing TB media (1 L) with ampicillin (100 µg mL-1), 
with incubation (37 °C, 200 rpm) until an optical density (A600nm) of 1.1 was reached. Protein 
expression was induced by the addition of isopropyl β-D-1-thiogalactopyranoside (0.5 mM), 
followed by overnight incubation (15 °C, 200 rpm). Cells were harvested by centrifugation (4 °C, 
4000 g, 20 minutes), then frozen. 
The cells were resuspended in 50 mL lysis buffer (50 mM Tris pH 8.0, 150 mM NaCl, 20 mM 
imidazole) with a tablet of cOmplete™ Protease Inhibitor Cocktail (Roche). The suspension was 
sonicated (15 minutes, 10 seconds on/ 20 seconds off) and centrifuged (4 °C, 30000 g, 20 minutes). 
The lysate was loaded onto a 7.5 mL nickel SepharoseTM fast flow column (GE Healthcare), pre-
equilibrated with lysis buffer. The column was washed with 5 column volumes of lysis buffer and 
eluted with buffer B (50 mM Tris pH 8.0, 150 mM NaCl, 300 mM imidazole) in 8 x 5 mL aliquots. 
Protein-containing aliquots, as determined by SDS-PAGE, were combined and concentrated (30 
kDa cutoff), then loaded onto a Superdex 200 HiloadTM 26/60 column (GE Healthcare) pre-
equilibrated with filtration buffer (10 mM Tris pH 8.0, 150 mM NaCl, 0.5 mM TCEP). 
Chromatography was conducted using an ÄKTATM FPLC system (GE Healthcare), with protein-
containing fractions, as determined by SDS-PAGE, combined and concentrated to 27.9 mg mL-1 
(24.3 mg L-1 yield), then flash-frozen in liquid nitrogen and stored at -80 °C. The identity of the 
protein was confirmed by LCMS analysis. 
Differential Scanning Fluorimetry. DSF was performed using a BioRad CFX Connect™ 
system, from 25 to 95 °C in 0.5 °C increments of 30 seconds duration. Samples were run in 96-
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well plates, with each well containing a final volume of 50 μL. Screening was conducted with 100 
mM Tris pH 7.5, 50 mM NaCl, 2.5x SyproOrange®, 2.5 μM Mtb fumarase and either 5% DMSO 
(control) or 5% ligand stock solution in DMSO. 
Biochemical Assay. The enzymatic activity of Mtb fumarase was followed by a CLARIOstar® 
microplate spectrometer (BMG Labtech) in a 96-well UV plate (Greiner). 2 μL of either DMSO 
(control) or ligand stock solution in DMSO was pipetted per well. 150 μL of a solution containing 
acetyl coenzyme A sodium salt (267 µM), β-nicotinamide adenine dinucleotide hydrate (200 µM), 
malate dehydrogenase (13.3 units mL-1), citrate synthase (1.33 units mL-1) and Mtb fumarase (33.3 
nM) in buffer (250 mM Tris pH 8.0, 5 mM MgCl2) was pipetted per well. The plate was left to 
equilibrate for 5 minutes at 25 °C, then 48 μL of either buffer (negative control) or fumaric acid 
(1.67 mM) (positive control or ligand) was pipetted per well. After 2 minutes the plate was read at 
a wavelength of 340 nm at intervals of 24 seconds over 10 minutes.  
Inhibition values for each ligand at a particular concentration were calculated from the gradient 
of the assay read over the 10 minutes, with correction by the negative control and normalization 
by the positive control. Inhibition experiments at 50 µM ligand concentration were performed at 
least twice (n ≥ 2), with % inhibition and standard error of the mean reported. IC50 experiments (n 
= 6) were performed with 10 ligand concentrations, obtained through serial dilution. Dose-
response curves were calculated using Origin software (OriginLab, Northampton, MA, USA), with 
IC50 and standard error reported. 
Soaking of Mycobacterium tuberculosis fumarate hydratase Crystals. Crystals were grown 
in Intelli-Plate® 24-4 well sitting drop plates (Art Robbins Instruments), incubated at 19 °C in a 
ROCK IMAGER® 1000 system (FORMULATRIX®). A sitting drop was set up with 2 µL protein 
solution (14 mg mL-1 Mtb fumarase, 150 mM NaCl, 10 mM Tris pH 8.0 and 0.5 mM TCEP) and 
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1 µL reservoir solution (10% w/v PEG3350, 5% DMSO and 0.30 M magnesium formate), 
equilibrated against 400 μL reservoir solution. After 3 weeks the resultant crystals were used to 
make seed stocks to produce reliable crystals for ligand screening. Sitting drops were set up with 
3 µL protein solution (14 mg mL-1 Mtb fumarase, 150 mM NaCl, 10 mM Tris pH 8.0 and 0.5 mM 
TCEP), 1 µL reservoir solution (10 – 11.4% w/v PEG3350, 5% DMSO and 0.30 M magnesium 
formate) and 0.5 µL seed stock, equilibrated against 400 μL reservoir solution. After 1 – 2 weeks 
drops were treated with 2 µL soaking solution (0.5 – 3 mM ligand, 7.5% DMSO, 26.25% w/v 
PEG3350 and 0.20 M magnesium formate) and incubated overnight. Crystals were mounted into 
loops and flash frozen in liquid nitrogen. 
X-ray Data Collection and Processing. X-ray data were collected on beamlines I03 and I04 at 
the Diamond Light Source synchrotron. Data was processed using autoPROC.18 Molecular 
replacement for the structure of Mtb fumarase in complex with 16b was carried out using 
PHASER,19 accessed through the CCP4 software suite,20 with the previously published 1-bound 
Mtb fumarase structure (PDB code 5F91) used as a search model.14 For structures of Mtb fumarase 
in complex with 15a, 15g, 16a, 16h, 16j or 16l, the solved 16b-bound structure was used as a 
search model. Models were manually rebuilt using the COOT molecular graphics software 
package,21 and refined with REFMAC5,22 accessed through CCP4.20 All coordinates have been 
deposited to the Protein Data Bank and the accession numbers, with data collection statistics 
compiled using PHENIX,23 are presented in Table S1. 
Screening against H37Rv Mycobacterium tuberculosis. Antimicrobial susceptibility testing 
against Mycobacterium tuberculosis H37Rv was performed in various media including: GAST-
Fe, 7H9/ADC, 7H9/DPPC (4.7 g/L 7H9 base, 14 mg/L DPPC, 0.81 g/L NaCl, 0.3 g/L Casitone, 
and 0.05% Tyloxapol) and 7H9/Glucose (4.7 g/L 7H9 base, 4 g/L glucose, 0.81 g/L NaCl, 0.3 g/L 
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Casitone, and 0.05% Tyloxapol). H37Rv was grown in the corresponding media to OD 0.2-0.4 
prior to use. 50 µL of a two-fold serial dilution series was placed in each well of a sterile 96-well 
round bottom plate, then 50 µL of H37Rv diluted to OD 0.0002 was added. Plates were incubated 
at 37 °C for two weeks prior to determining MIC. The MIC is defined here as the drug 




The following files are available free of charge. 
Synthesis of intermediates, Biochemical Assay Dose-response Curves (Figures S1 to S7), X-ray 
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collection and refinement statistics (Table S1) (PDF) 
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Accession Codes 
Atomic coordinates for the X-ray structures of compounds 1 (PDB code 5F91), 15a (PDB code 
6S74), 15g (PDB code 6S7W), 16a (PDB code 6S7K), 16b (PDB code 6S43), 16j (PDB code 
6S7Z), 16l (PDB code 6S88) and 16h (PDB code 6S7S) are available from the RCPB Protein Data 
Bank (www.rcpb.org). Authors will release the atomic coordinates and experimental data upon 
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